

# Cancer Incidence and Mortality in New Jersey 2000 - 2004

Prepared by:

Xiaoling Niu, MS

Stasia S. Burger, MS, CTR

Susan Van Loon, RN, CTR

Betsy A. Kohler, MPH, CTR

Cancer Epidemiology Services

Public Health Services Branch

New Jersey Department of Health and Senior Services

Eddy A. Bresnitz, MD, MS

Deputy Commissioner/State Epidemiologist

New Jersey Department of Health and Senior Services

Fred M. Jacobs, MD, JD

Commissioner

New Jersey Department of Health and Senior Services

Jon S. Corzine

Governor

Cancer Epidemiology Services

New Jersey Department of Health and Senior Services

PO Box 369

Trenton, NJ 08625-0369

(609) 588-3500

<http://nj.gov/health/ces/index.shtml>

March 2007



## ACKNOWLEDGMENTS

The following staff of the New Jersey State Cancer Registry and the Cancer Surveillance Program of the Cancer Epidemiology Services were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

Pamela Agovino, MPH	Harrine Katz, CTR
Anne Marie Anepete, CTR	Joan Kay, CTR
Pamela Beasley	Mireille Lemieux
Tara Blando	Thuy Lam, MPH
Donna Brown-Horn, CTR	Henry Lewis, MPH
Emiliano Cornago, CTR	Helen Martin, CTR
Phyllisann Danley	Ilsia Martin, MS
Kathleen Diszler, RN, CTR	Kevin Masterson, CTR
Thomas English, CTR	Carl C. Monetti
Lorraine Fernbach, CTR	John Murphy, CTR
Ruthann Filipowicz	Lisa Paddock, MPH
Raj Gona, MPH, MA	Maithili Patnaik, CTR
Cynthia Grayon, CTR	Theresa Pavlovcak, CTR
Maria Halama, MD, CTR	Karen Pawlish, MPH, ScD
Essam Hanani, MD, CTR	Barbara Pingitor
Denise Hansen	Gladys Pyatt-Dickson, CTR
Marilyn Hansen, CTR	Karen Robinson-Frasier, CTR
Kevin Henry, PhD	Antonio Savillo, MD, CTR
Joan Hess, RN, CTR	Suzanne Schwartz, MS, CTR
Margaret Hodnicki, RN, CTR	Felicia Stewart
Yvette Humphries	Celia Troisi, CTR
Nicole Jackson	Helen Weiss, RN, CTR
Linda Johnson, CTR	Michael Wellins
Anna Jones	Homer Wilcox III, MS
Catherine Karnicky, CTR	

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract HHSN261200544005C ADB No. N01-PC-54405, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement U55/CCU221914, and the State of New Jersey.

## TABLE OF CONTENTS

Introduction.....	1
Summary.....	2
Technical Notes.....	4
New Jersey State Cancer Registry.....	4
Data Sources an Specifications.....	6
Data Presentation.....	8
References.....	11

## TABLES

Table 1.	Age-adjusted Incidence Rates, Males (all races combined).....	14
Table 2.	Age-adjusted Incidence Rates, Females (all races combined).....	16
Table 3.	Age-adjusted Incidence Rates, White Males.....	18
Table 4.	Age-adjusted Incidence Rates, White Females.....	20
Table 5.	Age-adjusted Incidence Rates, Black Males.....	22
Table 6.	Age-adjusted Incidence Rates, Black Females.....	24
Table 7.	Age-adjusted Incidence Rates, Hispanic Males and Females (combined years)...	26
Table 8.	Comparative Incidence Rates, New Jersey and U.S., 1999-2003: Males.....	28
Table 9.	Comparative Incidence Rates, New Jersey and U.S., 1999-2003: Females.....	28
Table 10.	Age-adjusted Mortality Rates, Males (all races combined).....	30
Table 11.	Age-adjusted Mortality Rates, Females (all races combined).....	32
Table 12.	Age-adjusted Mortality Rates, White Males.....	34
Table 13.	Age-adjusted Mortality Rates, White Females.....	36
Table 14.	Age-adjusted Mortality Rates, Black Males.....	38
Table 15.	Age-adjusted Mortality Rates, Black Females.....	40
Table 16.	Age-adjusted Mortality Rates, Hispanic Males and Females(combined years)...	42
Table 17.	Comparative Mortality Rates, New Jersey and U.S., 1999-2003: Males.....	44
Table 18.	Comparative Mortality Rates, New Jersey and U.S., 1999-2003: Females.....	44
Table 19.	Population Denominators.....	45
Table 20.	Age Distribution of Cancer Incidence.....	47
Table 21.	Median Age at Cancer Diagnosis.....	48



## INTRODUCTION

This report presents statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 2000-2004, age-adjusted mortality rates and counts for the period 2000-2003 and comparisons of state and national rates for 1999-2003. The New Jersey cancer incidence data for 2004 are considered preliminary. U.S. cancer incidence data and cancer mortality data for 2004 are not yet available.

The primary goal of this report is to provide 2000-2004 cancer data to health planners, researchers and the public. Data are provided statewide for six population subgroups: white men, white women, black men, black women, Hispanic men and Hispanic women. Data are also provided by gender for all races combined.

For each year, the age-adjusted incidence and mortality rates per 100,000 population are shown for 69 categories of cancer and for all sites combined. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the data tables. These conventions are standard practice for publication of cancer rates in the United States.

Additional New Jersey cancer incidence, mortality, and survival data are available, or will be soon, from the Cancer Epidemiology Services office or on our website, <http://nj.gov/health/ces/index.shtml>, including:

- *Trends in Cancer Incidence and Mortality in New Jersey 1979-2002*;
- *Cancer Incidence Rates in New Jersey's Ten Most Populated Municipalities 1998-2002*;
- *Cancer Survival in New Jersey 1979-1997*;
- *Cancer Prevalence in New Jersey on January 1, 2003*; and
- *Childhood Cancer in New Jersey 1979-2002*.

Our new interactive cancer data mapping application provides incidence and mortality counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 2000-2004 at <http://www.cancer-rates.info/nj/>. Other New Jersey and U.S. cancer data can be found on the following websites:

- Cancer Control Planet <http://cancercontrolplanet.cancer.gov/>
- North American Association of Central Cancer Registries' *Cancer in North America 1999-2003* <http://www.naaccr.org/cancerinnorthamerica>
- Surveillance, Epidemiology and End Results Program (SEER) Cancer Statistics <http://surveillance.cancer.gov/statistics/>

## SUMMARY

### NEW JERSEY CANCER INCIDENCE AND MORTALITY DATA, 2000-2004

A total of 44,985 cases of invasive cancer diagnosed in 2004 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), compared to 45,248 reported cases diagnosed in 2003. During the period 2000-2004, a total of 230,761 cases of invasive cancer were diagnosed among New Jersey residents, 51 percent among men and 49 percent among women.

In New Jersey, between 2000 and 2004, overall age-adjusted total cancer incidence rates increased for men and women through 2001 and then declined. New Jersey black men continued to have the highest cancer incidence rates, and black women continued to have the lowest cancer incidence rates for all sites combined. The lower New Jersey incidence rates for prostate cancer in 2003 and 2004, compared to earlier years, may be due to reduced screening, delays in reporting or for other reasons currently unknown. Incidence rates for thyroid cancer continued to increase statewide between 2000 and 2004, especially among white women. New Jersey Hispanics continued to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population including lung, colorectal, breast, bladder, and melanoma of the skin. Hispanics also continued to have higher incidence rates for cervical, stomach and liver cancers compared with the general population.

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in North America* by the North American Association of Central Cancer Registries (NAACCR) for 1999-2003, New Jersey incidence rates for all cancers combined continued to be higher than the U.S. rates. New Jersey had higher incidence rates compared to the U.S. for the most common cancers with some exceptions. New Jersey incidence rates were lower than U.S. rates for male lung cancer among whites, blacks and all races combined.

Among New Jersey residents, a total of 17,957 deaths occurred in 2003 for which cancer was designated on the death certificate as the underlying cause, compared to 17,827 reported cancer deaths in 2002. During the period 2000-2003, a total of 73,020 cancer deaths occurred among New Jersey residents, 49 percent among men and 51 percent among women. In New Jersey, between 2000 and 2003, overall age-adjusted cancer mortality rates continued to slowly decline, similar to the trend observed throughout the nation.

New Jersey cancer mortality rates for men continued to be higher than for women. Cancer mortality rates for black men continued to be higher than for white men. Among black women, cancer mortality rates continued to be slightly higher compared to white women. Overall cancer mortality rates for New Jersey Hispanic men and women were much lower than for all men and women in New Jersey except for liver cancer, for which the rate was similar. Mortality rates were generally higher for Hispanic men compared with Hispanic women, which is consistent with the pattern seen among all races/ethnicities combined.



For the period 1999-2003, the New Jersey cancer mortality rate for all cancer sites combined was higher than the corresponding rate for the U.S. for both men and women. However, lung cancer mortality rates among men for all races combined, whites, and blacks, were lower for New Jersey than the U.S. New Jersey black men continued to have lower mortality rates for the most common cancers compared to U.S. black men. Among women, the cancer mortality rates for all sites combined, breast and colorectal cancers were higher for New Jersey than the U.S. during this period. Lung, breast and colorectal cancer mortality rates for New Jersey women were similar to the corresponding rates for the U.S.

## TECHNICAL NOTES

### New Jersey State Cancer Registry (NJSCR)

#### NJSCR Overview

The objectives of the New Jersey State Cancer Registry (NJSCR) are to:

- \* monitor cancer trends in New Jersey;
- \* promote scientific research;
- \* respond to New Jersey residents about cancer concerns;
- \* educate the public;
- \* provide information for planning and evaluating cancer prevention and control activities; and
- \* share and compare cancer data with other states and the nation.

The New Jersey State Cancer Registry is a population-based cancer incidence registry that serves the entire state of New Jersey, which has a current estimated population of over 8.6 million people. The NJSCR was established by legislation (NJSA 26:2-104 et. seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (NJAC 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, reporting agreements are maintained with New York, Pennsylvania, Delaware, Florida, Maryland, and North Carolina so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the Registry by: requiring electronic reporting; requiring abstracting by certified tumor registrars; and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) determined annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O)*, 2<sup>nd</sup> edition for cancers diagnosed through 2000 and the 3<sup>rd</sup> edition for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the North American Association of Central Cancer Registries (NAACCR), an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a National Cancer Institute (NCI) SEER Registry.

### **NJSCR Data Quality**

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each year 1995 through 2003. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulas, it is possible for the estimation of completeness to be greater than 100 percent. For 2004 data, the completeness of case reporting was estimated as 102.5 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the cancer rates, or alter the overall trends presented in this report.

Other 2004 cancer incidence data quality indicators measured as follows:

- percent death-certificate-only cases - 1.4 percent;
- percent of unresolved duplicates - < 0.01 percent;
- percent of cases with unknown race - 1.7 percent;
- percent of cases with unknown county - 0.04 percent;
- number of cases with unknown age - 14 and
- number of cases with unknown gender - 2.

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to ongoing editing and review of the data. At the time we prepared 2003 rates in the last report, we used 2002 population since 2003 population was not available. The 2003 incidence rates for total cancer in this report decreased by 1.5% for both men and women. 2004 incidence rates presented here are based on 2004 population estimates but the case counts are expected to change by the time all data are complete, and therefore are considered preliminary.

The NJSCR continues to work toward improving the quality and number of its reporting sources. Over the past few years, significant improvements have been realized in this regard. For example

some of these improvements have resulted in better reporting of skin cancers such as melanoma. One of the most significant improvements has been the implementation of electronic pathology laboratory reporting (E-path) from a national pathology laboratory and several hospital-based laboratories. The ultimate goal is to enable E-path laboratory reporting from every laboratory that serves New Jersey. E-path reporting is expected to improve the timeliness and completeness of cancer reporting, especially for non-hospitalized cases.

## **Data Sources and Specifications**

### **Incidence Data**

New Jersey cancer incidence data were taken from the January 2007 analytic file of the New Jersey State Cancer Registry. All the counts and rates were tabulated using SEER\*Stat Version 6.2 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America 1999-2003* (<http://www.naaccr.org/cancerinnorthamerica>).

This report also presents incidence rates and counts for two rare cancers, Kaposi sarcoma (KS) and mesothelioma. KS is a cancer of connective tissue such as cartilage, bone, fat, muscle, and blood vessels. Since the vast majority of KS cases have developed in association with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), HIV/AIDS is listed as the underlying cause of death. Therefore, KS mortality rates were not included in this report. Mesothelioma is a cancer that generally occurs in the chest, abdominal region, and areas surrounding the heart. It is typically associated with exposure to asbestos.

Beginning with the year 2001, the coding scheme for incident cancer cases changed from the *International Classification of Diseases for Oncology, 2<sup>nd</sup> edition (ICD-O-2)* to the *3<sup>rd</sup> edition (ICD-O-3)*. When cases in 1979-2000 are converted from ICD-O-2 to ICD-O-3, some cancers (mainly ovarian cancer) yield an ICD-O-3 borderline behavior. Also, when 2001+ cases are converted from ICD-O-3 to ICD-O-2, some cancers yield an ICD-O-2 borderline behavior. We used SEER behavior recode for analysis to select invasive cancers. For definition, visit SEER Behavior Recode for Analysis on SEER web site: <http://www.seer.cancer.gov/behavrecode/>. By this definition, invasive cancer means the case had a behavior of malignant in both ICD-O-2 and ICD-O-3.

In October 2002, President Bush signed Public Law 107-260, the Benign Brain Tumor Cancer Registries Act which requires the reporting of nonmalignant brain tumors beginning with cases diagnosed on or after January 1, 2004.

### **Exclusions**

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with the standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 2000-2004 is 151, representing 0.07% of the total case population. The small numbers of cases with unknown age, gender or race were also excluded from the analyses. Since the number of records so affected was very small, the rates were virtually

unaffected by the non-inclusion of these records. Race-specific information is not shown separately for persons who are races other than white or black (including unknown race), but these persons are included in the "all races" data. Only invasive cancers were included in the incidence data, except *in situ* bladder cancers were included. Invasive means that a cases had malignant behavior in both ICD-O-2 and ICD-O-3. Some cancers were excluded from the analysis by this definition. Myelodysplastic syndrome, for example, was reclassified in ICD-O-3 (effective diagnosis year 2001) from nonmalignant to malignant; other cancers so reclassified include endometrial stromal sarcoma (low grade), papillary ependymoma, papillary meningioma, polycythemia vera, chronic myeloproliferative disease (NOS), myelosclerosis with myeloid metaplasia, essential thrombocythemia, refractory anemia, refractory anemia with sideroblasts, refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation. In contrast, borderline tumors of the ovary were reclassified from malignant to nonmalignant at the same time. These cancers were excluded from the analysis. Starting with diagnosis year 2001, pilocytic astrocytoma was reclassified as malignant and was not excluded.

## **Mortality Data**

New Jersey cancer mortality data in 2000-2003 were obtained through the NCI's Surveillance, Epidemiology, and End Results (SEER) Program from the National Center for Health Statistics (NCHS) and tabulated using SEER\*Stat. At the time of this report, year 2004 mortality data were not yet available.

Cancer sites in mortality data were grouped according to the revised SEER Cause of Death Recode 1969+ (9/17/2004). The detailed information can be found on SEER web site (<http://seer.cancer.gov/codrecode/>). U.S. cancer mortality data were obtained from NAACCR's publication, *Cancer in North America 1999-2003* (<http://www.naaccr.org/cancerinnorthamerica>).

## **Population Data**

The 1999-2004 population estimates for this report were provided by the National Cancer Institute's SEER Program and downloaded from the SEER's website <http://seer.cancer.gov/popdata/>.

In the 2000 Census, individuals were given the opportunity to categorize themselves as more than one race, as specified in the 1997 Office of Management and Budget (OMB) standards ([http://www.whitehouse.gov/omb/fedreg/directive\\_15.html](http://www.whitehouse.gov/omb/fedreg/directive_15.html)) for the collection of data on race and ethnicity. For the first time, individuals could "mark [X] one or more races to indicate what this person considers himself/herself to be." The population estimates incorporate new bridged single-race estimates for July 1, 2000, 2001, 2002, 2003, and 2004 that are derived from the original multiple race categories in the 2000 Census. These estimates result from bridging the 31 race categories used in Census 2000 to the four single race categories specified under the 1977 OMB standards. Race bridging is a method used to make multiple-race and single-race data collection systems sufficiently comparable to permit estimation and analysis of race-specific statistics. The bridged single-race estimates and a description of the methodology used to develop them appear on the National Center for Health Statistics Web site (<http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>).

## **Description of Algorithm for Designating Hispanic Ethnicity**

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry during the years 1994-2004.

In 2005, NAACCR made several revisions to NHIA, now NHIA version 2. The most significant change in NHIA version 2 was the addition of an option for registries to not apply the algorithm to counties in which the Hispanic population is less than five percent. The New Jersey State Cancer Registry determined that this option did not enhance the accuracy of the NHIA and therefore opted not to apply this option. Thus, using NHIA version 2 will not affect the New Jersey cancer rates among Hispanics.

Prior to the development of the NHIA, the NJSCR used a method to assign Hispanic ethnicity to cases that was adapted from algorithms developed by the Illinois State Cancer Registry (ISCR) and by the NJSCR. NHIA is closely related to these former algorithms, so there is high agreement between the cases previously determined to be Hispanic and those currently determined to be Hispanic.

As a result of using the NHIA, the NJSCR was able to increase the number of Hispanic cases by 23 percent for this time period, thereby correcting an under-identification of Hispanics. For a more complete description of the NHIA version 2 and a copy of the NHIA SAS program visit the following link at the NAACCR website: <http://www.naaccr.org/datastandards>.

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g. black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority (89 percent) of Hispanics identify themselves as white. The Hispanics who identify themselves as white are included in the white race category as well as the all races category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the NHIA algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13 percent for men and 23 percent for women.

## **Data Presentation**

### **Suppression of Rates and Counts under Five**

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority

populations. Rates generated from small numbers should be interpreted with caution. For this report, rates were suppressed where counts were less than 5 as a way to ensure a greater level of statistical reliability and patient confidentiality.

### **Calculation of Rates**

All the counts and rates were tabulated using SEER\*Stat Version 6.2 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 1999-2003* (<http://www.naaccr.org/cancerinnorthamerica>).

### **Age-adjusted Rates and the Year 2000 Standard**

The U.S. Department of Health and Human Services requires that health data be age-adjusted using the U.S. Year 2000 population as a standard, beginning with the 1999 reporting year. Age-adjustment to the year 2000 population as the standard has been used in our last three annual reports. Prior to the release of 1999 data, various federal and state agencies calculated disease rates using different U.S. population standards, including the 1940 and 1970 standard populations. Our report *Cancer Incidence and Mortality in New Jersey, 1995-1999*, issued in September 2001, used the former 1970 population standard for all five years and also illustrated the effect on 1999 incidence rates of changing the population standard from 1970 to 2000.

Calculations using the 2000 standard population do not indicate a change in cancer incidence or occurrence—only a different representation of the rates of reported cancer. Using the 2000 population as the standard produces standardized cancer rates that appear to be about 20 percent higher than previously reported.

In this report, the 2000 U.S. Std. Population (19 age groups-Census P25-1130) was used for age-adjustment instead of the 2000 U.S. Std. Million (19 age groups). This has been standard practice for all NCI SEER reports with incidence or mortality data for 2002 or later. This new population standard was created for use with single year of age population data. Differences in the age-adjusted rates using the 2000 Std. Million and the new 2000 U.S. Std. Population are minimal. For further details, see SEER's website located at the following link [http://seer.cancer.gov/stdpopulations/single\\_age.html](http://seer.cancer.gov/stdpopulations/single_age.html).

### **Rate Calculation Formulas**

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where

$r_a$  = the age-specific rate for age group a,  
 $n_a$  = the number of events (cancer diagnoses) in the age group during the time interval,  
 $t$  = the length of the time interval (in years), and  
 $P_a$  = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization, which uses the following formula:

$$R = \frac{\sum_{a=1}^n r_a \times Std. P_a}{\sum_{a=1}^n Std. P_a}$$

where

$R$  = the age-adjusted rate,  
 $r_a$  = the age-specific rate for age group a, and  
 $Std.P_a$  = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.



## REFERENCES

Breslow NE and Day NE. Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies. New York: Oxford University Press.1987.

Chiang CL. "Standard error of the age-adjusted death rate". In Vital Statistics Special Reports, Volume 47, Number 9. USDHEW, PHS, Washington, D.C. U.S. Government Printing Office, 1961.

Howe HL, Wu X, Ries LA et al. Annual Report to the Nation on the Status of Cancer, 1975-2003, Featuring Cancer among U.S. Hispanic/Latino Populations. Cancer 2006; 107: 1711-42.

Ellison JH, Wu XC, McLaughlin C et al (eds). Cancer in North America, 1999-2003 Volumes 1-4. North American Association of Central Cancer Registries, May 2006. [URL. <http://www.naaccr.org/cancerinnorthamerica>, accessed January 16, 2007]

Fritz A., Percy C. Implementing ICD-O-3: Impact of the New Edition. SEER Program, National Cancer Institute. [URL. [http://training.seer.cancer.gov/module\\_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf](http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf) , accessed October 26, 2005]

Ingram DD, Parker JD, Schenker N et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. Vital Health Stat 2(135). 2003. [URL. [http://www.cdc.gov/nchs/data/series/sr\\_02/sr02\\_135.pdf](http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf), accessed October 26, 2005]

Martin, RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population". Topics in Health Statistics. Center for Health Statistics. 2000;01-02.

National Center for Health Statistics. U.S. census population with bridged race categories, September 2004. [URL. <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>, accessed October 26, 2005]

North American Association of Central Cancer Registries. Registry Operation Guidelines-Hispanic Identification. Springfield, Illinois: U.S. [URL. <http://www.naaccr.org/datastandards>, accessed October 26, 2006]

Rothman K. *Modern Epidemiology*. U.S. Little, Brown, and Company. 1986.

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)). Population estimates used in NCI's SEER\*Stat software, January 3, 2007. [URL <http://seer.cancer.gov/popdata/methods.html>, accessed January 16, 2007]

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov))  
SEER\*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2003),  
National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch,  
released April 2006. Underlying mortality data provided by NCHS ([www.cdc.gov/nchs](http://www.cdc.gov/nchs)). [URL.  
<http://seer.cancer.gov/mortality/>, accessed January 26, 2007]

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov))  
SEER\*Stat Database: Populations - Total U.S. (1969-2004), National Cancer Institute, DCCPS,  
Surveillance Research Program, Cancer Statistics Branch, released January 2007. [URL.  
<http://seer.cancer.gov/popdata/>, accessed January 16, 2007]

Surveillance Research Program, National Cancer Institute Seer\*Stat software Version 6.2. [URL.  
<http://seer.cancer.gov/seerstat/>, accessed September 26, 2006]

The United States Census Bureau. "Major differences in subject-matter content between 1990  
and 2000 Census questionnaires-race", October 2003. [URL.  
<http://www.census.gov/population/www/cen2000/90vs00.html>, accessed October 26, 2005]

Weinstein R, Lee YS and Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New  
Jersey Department of Health and Senior Services, June 2000. [URL.  
<http://www.state.nj.us/health/cancer/hispanic/>, accessed October 26, 2005]

**TABLES**

**Table 1. Age-adjusted Incidence Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>All Sites</b>	118,261	630.1	651.1	639.9	587.8	566.8
<b>Oral Cavity and Pharynx</b>	2,933	15.3	14.7	14.7	14.2	14.2
Lip	121	0.7	0.8	0.9	0.4	0.4
Tongue	886	4.1	4.4	4.3	4.4	4.6
Salivary Gland	318	1.8	1.7	1.6	1.6	1.5
Floor of Mouth	186	0.9	1.0	1.0	0.9	0.7
Gum and Other Mouth	363	2.0	1.8	1.9	1.9	1.8
Nasopharynx	168	1.0	0.8	0.9	1.0	0.5
Tonsil	425	2.1	1.8	1.9	2.2	2.2
Oropharynx	125	0.8	0.3	0.6	0.4	0.9
Hypopharynx	279	1.6	1.6	1.1	1.2	1.5
<b>Digestive System</b>	23,275	126.7	127.4	123.7	118.8	116.1
Esophagus	1,675	9.0	8.6	8.0	8.4	9.2
Stomach	2,492	12.5	14.0	14.2	12.6	12.6
Small Intestine	460	2.1	2.3	2.3	2.3	2.7
Colon and Rectum	13,259	76.1	73.6	71.6	67.1	63.1
Colon excluding Rectum	9,134	53.0	51.5	49.9	47.0	43.4
Rectum and Rectosigmoid Junction	4,125	23.1	22.2	21.7	20.1	19.8
Anus, Anal Canal and Anorectum	201	0.7	1.0	1.3	1.2	0.9
Liver and Intrahepatic Bile Duct	1,822	9.0	9.8	8.9	9.3	9.5
Liver	1,687	8.0	8.9	8.3	8.6	9.0
Intrahepatic Bile Duct	135	1.0	0.9	0.6	0.7	0.4
Gallbladder	196	1.0	1.1	0.9	1.4	0.9
Pancreas	2,609	13.6	14.3	13.5	13.6	13.9
<b>Respiratory System</b>	17,388	97.4	95.0	93.0	89.4	81.7
Larynx	1,483	8.2	8.3	7.4	7.2	6.6
Lung and Bronchus	15,659	88.0	85.4	84.2	80.9	74.1
<b>Bones and Joints</b>	255	1.0	1.5	1.3	1.2	1.2
<b>Soft Tissue (Including Heart)</b>	749	3.6	4.0	3.8	3.8	3.7
<b>Skin (Excluding Basal and Squamous)</b>	5,172	21.9	25.8	29.0	26.2	29.1
Melanoma of the Skin	4,793	19.8	23.6	26.8	24.6	27.2

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 1 (continued). Age-adjusted Incidence Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>Breast</b>	280	1.3	1.5	1.3	1.5	1.8
<b>Male Genital System</b>	38,669	210.8	221.4	223.2	181.0	164.6
Prostate	37,193	204.0	214.2	215.7	174.0	157.5
Testis	1,249	5.5	6.0	6.2	5.7	6.3
Penis	183	1.1	0.9	1.1	1.1	0.7
<b>Urinary System</b>	12,706	66.4	68.9	64.9	64.8	69.7
Urinary Bladder (Including in situ)	8,550	45.9	47.2	43.8	44.1	48.0
Kidney and Renal Pelvis	3,904	18.6	20.3	19.8	19.5	20.5
Ureter	169	1.1	1.1	0.8	0.7	0.8
<b>Eye and Orbit</b>	216	1.2	1.0	1.1	1.0	1.1
<b>Brain and Other Nervous System</b>	1,672	8.8	8.3	7.8	9.0	7.8
Brain	1,551	8.1	7.6	7.4	8.1	7.4
<b>Endocrine System</b>	1,356	6.2	5.9	6.9	6.7	7.1
Thyroid	1,165	5.2	4.7	6.0	5.9	6.3
<b>Lymphomas</b>	5,753	28.3	31.7	28.7	29.6	28.3
Hodgkin Lymphoma	749	3.3	3.9	3.3	4.1	3.4
Non-Hodgkin Lymphoma	5,004	25.0	27.8	25.4	25.5	24.9
<b>Myelomas</b>	1,425	8.0	7.7	7.9	6.5	7.5
<b>Leukemias</b>	3,253	15.6	18.4	16.9	16.8	16.8
Lymphocytic Leukemia	1,630	7.5	9.4	8.2	8.2	8.9
Acute Lymphocytic Leukemia	334	1.1	1.6	2.1	1.3	2.0
Chronic Lymphocytic Leukemia	1,163	5.6	6.8	5.5	6.5	6.2
Myeloid and Monocytic Leukemia	1,445	6.7	8.2	7.6	7.9	7.2
Acute Myeloid Leukemia	948	4.1	5.7	5.2	4.8	4.9
Acute Monocytic Leukemia	52	0.3	0.1	0.2	0.5	0.2
Chronic Myeloid Leukemia	398	2.2	2.1	2.1	2.3	1.7
Other Leukemia	178	1.4	0.9	1.1	0.8	0.7
<b>Mesothelioma</b>	566	3.1	3.5	3.0	3.0	3.0
<b>Kaposi Sarcoma</b>	231	1.3	1.1	1.2	1.1	1.0
<b>Ill-Defined &amp; Unspecified Sites</b>	2,362	13.0	13.2	11.8	13.2	12.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 2. Age-adjusted Incidence Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>All Sites</b>	112,500	452.2	462.3	447.5	434.9	439.2
<b>Oral Cavity and Pharynx</b>	1,496	5.8	6.0	5.8	5.9	6.3
Lip	74	0.2	0.3	0.2	0.4	0.3
Tongue	402	1.5	1.7	1.5	1.7	1.6
Salivary Gland	252	1.0	1.1	1.1	0.8	1.2
Floor of Mouth	104	0.4	0.3	0.5	0.4	0.5
Gum and Other Mouth	300	1.2	1.2	1.0	1.2	1.2
Nasopharynx	80	0.2	0.4	0.5	0.4	0.3
Tonsil	122	0.5	0.5	0.4	0.5	0.6
Oropharynx	59	0.3	0.2	0.2	0.2	0.3
Hypopharynx	72	0.3	0.3	0.3	0.2	0.3
<b>Digestive System</b>	21,468	83.5	84.1	82.1	80.2	76.3
Esophagus	611	2.3	2.5	2.4	2.5	2.0
Stomach	1,623	6.2	5.9	5.6	6.6	6.5
Small Intestine	418	1.3	1.6	1.8	1.9	1.7
Colon and Rectum	13,480	53.4	54.3	52.4	48.7	45.4
Colon excluding Rectum	10,208	39.9	41.5	39.2	36.7	33.8
Rectum and Rectosigmoid Junction	3,272	13.5	12.8	13.2	12.0	11.6
Anus, Anal Canal and Anorectum	387	1.6	1.6	1.5	1.4	1.7
Liver and Intrahepatic Bile Duct	799	3.1	3.1	2.8	3.1	3.2
Liver	644	2.2	2.5	2.3	2.7	2.6
Intrahepatic Bile Duct	155	0.8	0.6	0.5	0.4	0.6
Gallbladder	446	1.6	1.7	1.4	1.8	1.9
Pancreas	2,934	11.8	10.5	10.9	10.8	11.1
<b>Respiratory System</b>	14,738	57.5	59.0	58.8	57.1	55.9
Larynx	369	1.5	1.7	1.6	1.3	1.4
Lung and Bronchus	14,188	55.1	56.8	56.6	55.1	53.8
<b>Bones and Joints</b>	217	1.0	1.0	0.7	1.0	1.1
<b>Soft Tissue (Including Heart)</b>	724	3.1	3.0	3.0	2.8	3.2
<b>Skin (Excluding Basal and Squamous)</b>	3,909	13.7	16.2	17.8	15.7	17.0
Melanoma of the Skin	3,625	12.8	15.1	16.5	14.6	15.9
<b>Breast (Invasive)</b>	32,550	137.9	137.1	130.1	125.5	129.4
in situ (not included in All Sites)	8,488	33.7	34.7	35.2	36.7	35.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 2 (continued). Age-adjusted Incidence Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>Female Genital System</b>	14,027	58.5	61.4	56.7	54.9	53.4
Cervix Uteri	2,257	10.0	10.2	9.1	9.5	9.3
Corpus and Uterus, NOS	6,998	28.2	29.8	28.3	27.2	27.5
Corpus Uteri	6,759	27.2	28.9	27.5	26.2	26.5
Uterus, NOS	239	1.0	1.0	0.7	1.0	0.9
Ovary	3,793	16.2	17.1	15.4	14.4	13.3
Vagina	179	0.8	0.8	0.5	0.8	0.6
Vulva	620	2.5	2.5	2.7	2.3	2.0
<b>Urinary System</b>	5,852	21.5	23.0	23.4	20.9	24.5
Urinary Bladder (Including in situ)	3,260	12.8	12.5	12.1	11.1	13.3
Kidney and Renal Pelvis	2,444	8.2	9.8	10.6	9.3	10.7
Ureter	110	0.3	0.4	0.5	0.4	0.4
<b>Eye and Orbit</b>	156	0.7	0.9	0.5	0.6	0.5
<b>Brain and Other Nervous System</b>	1,427	6.1	6.0	5.3	5.9	6.6
Brain	1,288	5.5	5.5	4.8	5.1	6.0
<b>Endocrine System</b>	3,945	14.9	15.9	16.9	18.6	19.6
Thyroid	3,764	14.2	15.0	16.3	17.6	18.8
<b>Lymphomas</b>	5,236	21.4	21.5	21.1	20.9	20.4
Hodgkin Lymphoma	685	3.2	3.2	3.2	3.1	2.9
Non-Hodgkin Lymphoma	4,551	18.3	18.3	17.8	17.8	17.5
<b>Myelomas</b>	1,329	5.6	5.8	5.0	4.7	4.4
<b>Leukemias</b>	2,505	10.2	10.2	10.0	9.7	9.5
Lymphocytic Leukemia	1,189	4.8	4.6	5.1	4.6	4.6
Acute Lymphocytic Leukemia	297	1.5	1.1	1.4	1.6	1.3
Chronic Lymphocytic Leukemia	825	3.0	3.3	3.4	2.8	3.0
Myeloid and Monocytic Leukemia	1,156	4.6	5.0	4.3	4.5	4.5
Acute Myeloid Leukemia	800	3.1	3.5	3.0	3.1	3.3
Acute Monocytic Leukemia	44	0.2	-	0.2	0.2	0.1
Chronic Myeloid Leukemia	288	1.2	1.2	1.0	1.2	1.0
Other Leukemia	160	0.8	0.5	0.6	0.6	0.4
<b>Mesothelioma</b>	149	0.5	0.6	0.6	0.6	0.5
<b>Kaposi Sarcoma</b>	37	0.2	0.2	0.1	0.1	0.1
<b>Ill-Defined &amp; Unspecified Sites</b>	2,735	10.2	10.4	9.7	9.9	10.4

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 3. Age-adjusted Incidence Rates, White Males**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>All Sites</b>	100,319	631.0	646.2	635.1	581.6	559.9
<b>Oral Cavity and Pharynx</b>	2,392	14.5	14.1	14.3	14.3	13.6
Lip	115	0.8	0.9	1.0	0.4	0.4
Tongue	742	4.0	4.4	4.3	4.4	4.7
Salivary Gland	276	1.9	1.7	1.6	1.7	1.4
Floor of Mouth	147	0.9	0.8	1.0	0.9	0.7
Gum and Other Mouth	300	1.8	1.8	1.9	1.8	1.7
Nasopharynx	111	0.7	0.7	0.7	0.8	0.3
Tonsil	345	2.1	1.7	1.7	2.3	2.1
Oropharynx	104	0.7	0.3	0.6	0.5	0.9
Hypopharynx	211	1.2	1.5	1.1	1.1	1.3
<b>Digestive System</b>	19,618	125.7	124.8	120.3	116.5	113.9
Esophagus	1,387	8.7	7.9	8.0	8.2	9.2
Stomach	1,984	11.7	12.7	13.2	11.8	11.6
Small Intestine	376	2.0	2.2	2.2	2.3	2.5
Colon and Rectum	11,419	76.9	73.5	71.1	66.4	63.5
Colon excluding Rectum	7,862	53.2	51.2	49.4	46.1	43.8
Rectum and Rectosigmoid Junction	3,557	23.7	22.4	21.7	20.3	19.7
Anus, Anal Canal and Anorectum	157	0.6	1.0	1.1	1.2	0.9
Liver and Intrahepatic Bile Duct	1,375	8.5	8.8	7.6	8.5	8.2
Liver	1,250	7.4	7.8	7.0	7.7	7.7
Intrahepatic Bile Duct	125	1.1	0.9	0.7	0.8	0.5
Gallbladder	170	1.0	1.2	0.8	1.4	0.9
Pancreas	2,277	13.6	14.7	13.6	13.8	14.0
<b>Respiratory System</b>	14,851	96.1	94.2	91.6	89.2	81.8
Larynx	1,212	7.7	7.9	7.1	7.2	6.3
Lung and Bronchus	13,426	87.0	85.2	83.2	80.6	74.4
<b>Bones and Joints</b>	207	1.1	1.7	1.2	1.1	1.2
<b>Soft Tissue (Including Heart)</b>	627	3.7	4.2	4.0	3.7	3.5
<b>Skin (Excluding Basal and Squamous)</b>	4,994	25.2	29.7	33.1	30.0	32.6
Melanoma of the Skin	4,655	22.9	27.4	30.8	28.2	30.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.



**Table 3 (continued). Age-adjusted Incidence Rates, White Males**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>Breast</b>	236	1.3	1.4	1.3	1.5	1.7
<b>Male Genital System</b>	31,354	204.9	211.7	213.8	167.1	151.8
Prostate	30,001	197.2	203.4	204.9	158.9	143.5
Testis	1,155	6.5	7.2	7.5	6.9	7.5
Penis	157	1.0	0.8	1.1	1.1	0.7
<b>Urinary System</b>	11,583	69.9	73.4	68.8	68.7	73.4
Urinary Bladder (Including in situ)	7,961	49.0	50.6	47.2	48.0	50.9
Kidney and Renal Pelvis	3,391	19.0	21.2	20.2	19.5	21.4
Ureter	159	1.2	1.2	0.9	0.8	0.8
<b>Eye and Orbit</b>	199	1.4	1.1	1.1	1.2	1.2
<b>Brain and Other Nervous System</b>	1,492	9.6	8.5	8.4	9.8	8.8
Brain	1,394	8.9	8.0	8.1	8.8	8.4
<b>Endocrine System</b>	1,173	6.5	6.0	7.5	7.2	7.5
Thyroid	1,010	5.5	4.7	6.4	6.4	6.8
<b>Lymphomas</b>	4,974	29.7	32.1	29.7	30.9	29.1
Hodgkin Lymphoma	632	3.4	4.3	3.7	4.7	3.4
Non-Hodgkin Lymphoma	4,342	26.3	27.9	26.0	26.2	25.8
<b>Myelomas</b>	1,126	7.5	7.0	7.3	5.9	6.8
<b>Leukemias</b>	2,799	16.4	19.1	16.7	17.2	16.8
Lymphocytic Leukemia	1,418	8.1	10.0	8.0	8.5	8.9
Acute Lymphocytic Leukemia	277	1.3	1.8	2.2	1.4	2.1
Chronic Lymphocytic Leukemia	1,020	5.9	7.1	5.2	6.7	6.1
Myeloid and Monocytic Leukemia	1,227	6.9	8.1	7.6	7.9	7.3
Acute Myeloid Leukemia	820	4.3	5.8	5.1	5.0	5.1
Acute Monocytic Leukemia	45	0.4	-	0.2	0.5	0.3
Chronic Myeloid Leukemia	322	2.1	1.9	2.1	2.2	1.6
Other Leukemia	154	1.4	1.0	1.1	0.7	0.7
<b>Mesothelioma</b>	535	3.3	3.6	3.2	3.3	3.2
<b>Kaposi Sarcoma</b>	149	1.1	0.9	0.9	0.9	0.8
<b>Ill-Defined &amp; Unspecified Sites</b>	2,010	12.9	12.8	11.8	13.1	11.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 4. Age-adjusted Incidence Rates, White Females**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>All Sites</b>	97,087	465.6	476.6	459.8	446.3	453.5
<b>Oral Cavity and Pharynx</b>	1,242	5.8	5.9	5.7	5.4	6.6
Lip	72	0.3	0.3	0.3	0.4	0.3
Tongue	345	1.5	1.7	1.6	1.6	1.7
Salivary Gland	200	1.0	1.0	1.0	0.8	1.3
Floor of Mouth	95	0.4	0.4	0.5	0.4	0.6
Gum and Other Mouth	250	1.2	1.2	1.1	1.0	1.3
Nasopharynx	47	0.2	0.2	0.4	0.2	0.2
Tonsil	102	0.4	0.5	0.4	0.5	0.7
Oropharynx	47	0.3	0.2	0.1	0.2	0.3
Hypopharynx	57	0.3	0.3	0.3	0.1	0.3
<b>Digestive System</b>	18,174	82.0	82.7	79.9	78.3	74.8
Esophagus	491	2.0	2.4	2.3	2.4	1.9
Stomach	1,275	5.5	5.0	5.0	6.3	6.0
Small Intestine	332	1.3	1.4	1.6	1.6	1.8
Colon and Rectum	11,566	53.5	54.3	51.6	47.4	45.2
Colon excluding Rectum	8,762	40.1	41.2	38.6	35.7	33.3
Rectum and Rectosigmoid Junction	2,804	13.4	13.1	13	11.8	11.9
Anus, Anal Canal and Anorectum	339	1.7	1.7	1.5	1.4	1.8
Liver and Intrahepatic Bile Duct	640	2.7	3.1	2.6	2.8	2.8
Liver	507	1.9	2.4	2.1	2.5	2.3
Intrahepatic Bile Duct	133	0.8	0.7	0.5	0.3	0.6
Gallbladder	370	1.5	1.7	1.4	1.7	1.7
Pancreas	2,495	11.5	10.3	10.4	10.8	11.0
<b>Respiratory System</b>	12,986	59.6	61.4	61.3	59.1	56.9
Larynx	310	1.5	1.9	1.5	1.2	1.5
Lung and Bronchus	12,520	57.2	58.9	59.1	57.2	54.8
<b>Bones and Joints</b>	186	1.0	1.1	0.7	1.1	1.1
<b>Soft Tissue (Including Heart)</b>	576	2.9	3.0	3.0	2.6	3.1
<b>Skin (Excluding Basal and Squamous)</b>	3,752	16.3	19.4	21.0	18.3	20.0
Melanoma of the Skin	3,503	15.3	18.3	19.6	17.2	18.8
<b>Breast (Invasive)</b>	27,974	142.6	141.8	134.2	129.9	135.8
in situ (not included in All Sites)	7,319	35.2	36.4	38.0	38.3	38.0

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 4 (continued). Age-adjusted Incidence Rates, White Females**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>Female Genital System</b>	11,979	60.0	63.7	58.4	56.3	55.1
Cervix Uteri	1,701	9.2	9.7	8.6	9.2	8.9
Corpus and Uterus, NOS	6,145	29.9	31.6	29.9	28.2	29.1
Corpus Uteri	5,947	28.8	30.7	29.2	27.2	28.2
Uterus, NOS	198	1.0	0.9	0.6	1.1	0.9
Ovary	3,315	17.0	18.0	16.2	15.2	13.9
Vagina	134	0.7	0.8	0.5	0.6	0.6
Vulva	544	2.5	2.7	2.7	2.4	2.0
<b>Urinary System</b>	5,221	23.1	23.7	24.4	21.6	25.9
Urinary Bladder (including in situ)	2,967	14.0	13.3	12.6	11.8	14.2
Kidney and Renal Pelvis	2,128	8.7	9.8	11.1	9.4	11.2
Ureter	102	0.3	0.5	0.6	0.4	0.5
<b>Eye and Orbit</b>	147	0.9	0.9	0.5	0.7	0.6
<b>Brain and Other Nervous System</b>	1,251	6.6	6.4	5.5	6.7	7.0
Brain	1,136	6.0	5.8	4.9	5.9	6.6
<b>Endocrine System</b>	3,332	15.7	17.0	18.2	19.7	21.4
Thyroid	3,188	14.9	16.1	17.6	19.0	20.6
<b>Lymphomas</b>	4,603	22.7	22.7	22.5	21.7	21.1
Hodgkin Lymphoma	588	3.5	3.5	3.9	3.2	3.1
Non-Hodgkin Lymphoma	4,015	19.2	19.1	18.6	18.4	18.0
<b>Myelomas</b>	1,003	4.8	5.3	4.3	4.1	3.8
<b>Leukemias</b>	2,152	10.5	10.6	10.0	10.0	9.5
Lymphocytic Leukemia	1,030	5.0	5.0	5.1	4.9	4.5
Acute Lymphocytic Leukemia	244	1.6	1.3	1.4	1.8	1.3
Chronic Lymphocytic Leukemia	727	3.2	3.4	3.4	2.9	2.9
Myeloid and Monocytic Leukemia	992	4.8	5.1	4.3	4.6	4.5
Acute Myeloid Leukemia	691	3.2	3.7	3.1	3.0	3.3
Acute Monocytic Leukemia	41	0.3	-	0.2	0.2	0.2
Chronic Myeloid Leukemia	240	1.2	1.2	0.8	1.3	1.0
Other Leukemia	130	0.8	0.5	0.6	0.5	0.4
<b>Mesothelioma</b>	140	0.5	0.7	0.7	0.7	0.5
<b>Kaposi Sarcoma</b>	30	0.2	0.1	0.1	0.1	0.1
<b>Ill-Defined &amp; Unspecified Sites</b>	2,339	10.1	10.1	9.5	9.8	10.2

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 5. Age-adjusted Incidence Rates, Black Males**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>All Sites</b>	13,243	714.7	739.5	689.7	664.0	624.4
<b>Oral Cavity and Pharynx</b>	420	22.7	19.6	18.7	14.4	22.4
Lip	-	-	-	-	-	-
Tongue	108	5.3	4.6	5.2	4.4	6.4
Salivary Gland	35	0.9	1.8	1.5	-	2.4
Floor of Mouth	32	-	2.9	1.4	-	-
Gum and Other Mouth	45	3.7	1.9	2.3	1.7	1.4
Nasopharynx	30	1.4	1.0	2.0	1.1	1.3
Tonsil	69	2.9	2.7	2.8	2.3	4.0
Oropharynx	20	2.1	-	1.1	-	1.3
Hypopharynx	59	4.2	2.8	1.5	1.9	3.9
<b>Digestive System</b>	2,666	149.6	148.4	147.1	145.3	130.0
Esophagus	250	14.9	14.9	10.0	13.2	10.6
Stomach	333	18.5	21.0	20.4	16.5	17.1
Small Intestine	66	3.0	3.0	4.0	2.8	3.5
Colon and Rectum	1,382	83.0	77.2	78.5	81.5	66.2
Colon excluding Rectum	1,011	60.5	57.3	60.6	64.1	47.2
Rectum and Rectosigmoid Junction	371	22.5	19.8	17.9	17.4	19.1
Anus, Anal Canal and Anorectum	41	1.1	1.9	2.3	1.5	1.4
Liver and Intrahepatic Bile Duct	269	10.4	16.0	11.5	11.8	14.1
Liver	262	10.2	15.4	11.3	11.2	14.1
Intrahepatic Bile Duct	7	-	-	-	-	-
Gallbladder	13	-	-	-	-	-
Pancreas	256	15.8	11.4	15.1	14.9	13.7
<b>Respiratory System</b>	2,128	122.7	121.1	117.4	107.8	98.5
Larynx	238	14.4	13.0	11.0	9.2	11.9
Lung and Bronchus	1,868	107.6	106.4	105.5	98.3	85.5
<b>Bones and Joints</b>	27	-	-	1.2	1.4	0.7
<b>Soft Tissue (Including Heart)</b>	93	3.9	3.5	2.5	5.2	5.2
<b>Skin (Excluding Basal and Squamous)</b>	40	1.4	2.8	2.0	-	1.6
Melanoma of the Skin	15	-	1.2	-	-	-

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 5 (continued). Age-adjusted Incidence Rates, Black Males**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>Breast</b>	35	-	2.6	1.7	1.4	2.3
<b>Male Genital System</b>	5,435	298.4	315.2	287.9	276.7	244.3
Prostate	5,363	295.2	311.7	286	273.4	242.2
Testis	53	1.3	2.0	1.7	2.2	1.6
Penis	17	1.7	1.2	-	-	-
<b>Urinary System</b>	745	42.9	38.8	35.6	36.5	41.4
Urinary Bladder (Including in situ)	349	24.6	21.9	15.6	14.2	23.8
Kidney and Renal Pelvis	382	17.5	16.4	19.1	21.5	16.7
Ureter	5	-	-	-	-	-
<b>Eye and Orbit</b>	8	-	-	-	-	-
<b>Brain and Other Nervous System</b>	105	4.1	5.9	3.2	4.7	3.1
Brain	92	3.9	4.9	2.6	4.4	2.8
<b>Endocrine System</b>	95	6.3	3.4	2.8	4.0	3.0
Thyroid	75	4.0	2.5	2.7	3.3	2.7
<b>Lymphomas</b>	544	20.0	25.0	23.2	21.0	23.8
Hodgkin Lymphoma	85	3.2	2.8	2.3	2.0	4.5
Non-Hodgkin Lymphoma	459	16.8	22.1	20.9	19.0	19.2
<b>Myelomas</b>	256	14.5	15.7	14.1	12.0	15.3
<b>Leukemias</b>	265	8.8	14.2	14.2	14.1	13.0
Lymphocytic Leukemia	111	3.1	5.5	8.6	4.4	5.7
Acute Lymphocytic Leukemia	37	-	0.7	2.5	1.3	1.1
Chronic Lymphocytic Leukemia	68	2.6	4.6	5.9	3.0	3.4
Myeloid and Monocytic Leukemia	139	5.1	8.3	5.4	8.3	6.7
Acute Myeloid Leukemia	80	2.2	5.2	4.6	4.4	3.5
Acute Monocytic Leukemia	5	-	-	-	-	-
Chronic Myeloid Leukemia	50	2.7	2.6	-	3.5	2.3
Other Leukemia	15	-	-	-	1.4	-
<b>Mesothelioma</b>	23	-	2.7	-	-	1.4
<b>Kaposi Sarcoma</b>	72	2.8	1.8	2.9	2.4	2.7
<b>Ill-Defined &amp; Unspecified Sites</b>	286	14.7	18.2	13.9	15.0	15.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 6. Age-adjusted Incidence Rates, Black Females**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>All Sites</b>	11,447	414.3	404.0	411.8	394.7	384.8
<b>Oral Cavity and Pharynx</b>	162	4.7	4.2	6.3	8.3	4.3
Lip	-	-	-	-	-	-
Tongue	33	0.9	1.3	1.0	1.5	0.9
Salivary Gland	29	-	1.0	1.4	1.1	0.9
Floor of Mouth	8	-	-	-	-	-
Gum and Other Mouth	36	1.3	0.9	1.2	2.5	-
Nasopharynx	12	-	-	-	-	-
Tonsil	19	-	-	-	0.9	-
Oropharynx	11	-	-	-	-	-
Hypopharynx	10	-	-	-	-	-
<b>Digestive System</b>	2,549	95.1	96.8	98.0	92.3	85.7
Esophagus	101	4.8	3.2	3.5	3.6	2.8
Stomach	240	9.9	10.8	8.2	7.7	8.4
Small Intestine	70	1.0	3.1	2.5	3.9	1.5
Colon and Rectum	1,510	56.1	58.5	59.0	54.9	48.3
Colon excluding Rectum	1,177	42.7	46.9	44.9	44.1	38.6
Rectum and Rectosigmoid Junction	333	13.4	11.6	14.0	10.8	9.6
Anus, Anal Canal and Anorectum	40	0.9	1.1	1.2	1.9	1.6
Liver and Intrahepatic Bile Duct	102	3.9	3.4	2.7	4.0	4.4
Liver	87	2.8	3.2	2.6	3.4	3.6
Intrahepatic Bile Duct	15	1.1	-	-	-	-
Gallbladder	54	2.1	1.9	1.0	2.8	2.2
Pancreas	364	15.3	12.2	16.4	11.7	13.5
<b>Respiratory System</b>	1,508	52.3	53.2	54.4	53.4	58.7
Larynx	55	2.0	-	2.9	2.4	1.8
Lung and Bronchus	1,435	49.6	51.9	51.0	50.8	56.2
<b>Bones and Joints</b>	18	-	-	-	-	1.1
<b>Soft Tissue (Including Heart)</b>	115	4.4	3.7	3.4	4.2	3.2
<b>Skin (Excluding Basal and Squamous)</b>	57	1.3	1.2	2.1	2.9	2.2
Melanoma of the Skin	29	1.0	-	0.9	1.5	1.3
<b>Breast (Invasive)</b>	3,302	124.2	115.0	115.4	105.7	102.4
in situ (not included in All Sites)	749	22.6	26.1	23.3	27.2	26.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 6 (continued). Age-adjusted Incidence Rates, Black Females**

Cancer Site	Total Cases	Rates				
		2000	2001	2002	2003	2004 Prelim.
<b>Female Genital System</b>	1,517	55.3	52.9	52.9	52.5	47.2
Cervix Uteri	438	17.9	13.5	13.6	12.9	14.1
Corpus and Uterus, NOS	634	21.2	24.3	23.4	23.9	19.4
Corpus Uteri	597	19.9	22.7	21.6	23.5	17.9
Uterus, NOS	37	1.3	1.6	1.8	-	1.5
Ovary	316	11.7	11.1	11.0	11.2	10.1
Vagina	35	1.6	1.5	-	1.6	0.9
Vulva	61	2.1	1.8	2.9	2.2	1.4
<b>Urinary System</b>	489	14.5	18.7	20.3	16.7	19.4
Urinary Bladder (Including in situ)	226	7.2	8.2	11.1	7.5	9.5
Kidney and Renal Pelvis	246	6.7	9.7	8.7	8.5	9.4
Ureter	-	-	-	-	-	-
<b>Eye and Orbit</b>	-	-	-	-	-	-
<b>Brain and Other Nervous System</b>	105	3.1	3.8	4.3	2.6	3.7
Brain	90	3.1	3.6	3.8	2.2	2.4
<b>Endocrine System</b>	314	9.7	9.4	9.0	12.0	9.8
Thyroid	291	9.6	8.8	8.1	10.8	9.0
<b>Lymphomas</b>	459	15.1	13.8	13.6	15.7	17.4
Hodgkin Lymphoma	77	2.7	2.2	1.2	2.9	2.7
Non-Hodgkin Lymphoma	382	12.4	11.6	12.4	12.8	14.7
<b>Myelomas</b>	290	13.4	9.5	11.9	8.7	9.6
<b>Leukemias</b>	226	8.8	7.8	7.5	7.4	7.8
Lymphocytic Leukemia	87	3.6	2.7	3.6	2.3	3.0
Acute Lymphocytic Leukemia	25	-	-	0.9	0.7	0.9
Chronic Lymphocytic Leukemia	59	2.7	1.9	2.7	1.6	2.0
Myeloid and Monocytic Leukemia	113	3.3	3.8	3.3	4.2	4.4
Acute Myeloid Leukemia	74	2.3	1.8	1.7	2.9	3.7
Acute Monocytic Leukemia	-	-	-	-	-	-
Chronic Myeloid Leukemia	34	0.9	2.0	1.3	1.0	-
Other Leukemia	26	1.8	1.3	-	0.9	-
<b>Mesothelioma</b>	6	-	-	-	-	-
<b>Kaposi Sarcoma</b>	6	-	-	-	-	-
<b>Ill-Defined &amp; Unspecified Sites</b>	321	11.6	13.0	12.3	10.9	11.8

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7. Age-adjusted Incidence Rates, Hispanic Males and Females  
2000-2004 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	539.6	7,776	365.3	7,454
<b>Oral Cavity and Pharynx</b>	13.0	214	4.3	83
Lip	0.5	6	0.4	5
Tongue	4.0	65	1.1	23
Salivary Gland	0.6	12	0.8	17
Floor of Mouth	0.4	9	0.3	6
Gum and Other Mouth	1.7	27	0.5	8
Nasopharynx	1.0	15	0.3	7
Tonsil	2.0	39	0.3	7
Oropharynx	0.9	14	-	-
Hypopharynx	1.4	22	0.3	5
<b>Digestive System</b>	122.0	1,726	85.5	1,511
Esophagus	6.5	96	2.9	44
Stomach	20.4	296	10.3	186
Small Intestine	2.5	34	1.8	34
Colon and Rectum	61.7	857	45.3	807
Colon excluding Rectum	41.8	559	32.8	571
Rectum and Rectosigmoid Junction	20.0	298	12.5	236
Anus, Anal Canal and Anorectum	0.5	11	1.9	38
Liver and Intrahepatic Bile Duct	13.2	207	5.2	88
Liver	12.4	195	4.3	72
Intrahepatic Bile Duct	0.8	12	0.9	16
Gallbladder	1.3	21	3.3	56
Pancreas	12.7	162	11.8	203
<b>Respiratory System</b>	67.2	892	31.5	550
Larynx	7.3	114	0.9	17
Lung and Bronchus	58.4	755	30.2	522
<b>Bones and Joints</b>	1.2	33	1.5	41
<b>Soft Tissue (Including Heart)</b>	2.9	62	2.8	71
<b>Skin (Excluding Basal and Squamous)</b>	7.0	113	5.0	113
Melanoma of the Skin	5.7	90	4.4	100
<b>Breast (Invasive)</b>	1.0	15	99.9	2,175
in situ (not included in All Sites)	-	-	23.8	529

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.



**Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males and Females  
2000-2004 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	**	**	51.7	1,143
Cervix Uteri	**	**	15.6	401
Corpus and Uterus, NOS	**	**	21.4	432
Corpus Uteri	**	**	20.5	412
Uterus, NOS	**	**	1.0	20
Ovary	**	**	11.3	246
Vagina	**	**	0.5	11
Vulva	**	**	2.3	39
<b>Male Genital System</b>	193.6	2,696	**	**
Prostate	187.3	2,506	**	**
Testis	4.0	151	**	**
Penis	1.9	35	**	**
<b>Urinary System</b>	50.5	647	17.4	323
Urinary Bladder (Including in situ)	33.4	383	8.6	149
Kidney and Renal Pelvis	15.3	245	8.4	168
Ureter	1.0	11	0.3	5
<b>Eye and Orbit</b>	0.9	16	0.4	9
<b>Brain and Other Nervous System</b>	7.5	151	5.3	131
Brain	7.2	142	4.6	114
<b>Endocrine System</b>	4.6	100	15.8	422
Thyroid	4.0	88	15.1	405
<b>Lymphomas</b>	29.3	520	18.1	392
Hodgkin Lymphoma	3.9	98	2.5	74
Non-Hodgkin Lymphoma	25.5	422	15.6	318
<b>Myelomas</b>	9.8	130	6.0	102
<b>Leukemias</b>	13.8	250	9.1	200
Lymphocytic Leukemia	5.8	116	4.1	95
Acute Lymphocytic Leukemia	1.8	62	2.0	56
Chronic Lymphocytic Leukemia	3.6	44	2.0	35
Myeloid and Monocytic Leukemia	6.9	117	4.4	93
Acute Myeloid Leukemia	4.7	80	3.4	71
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	1.8	32	0.8	18
Other Leukemia	1.2	17	0.6	12
<b>Mesothelioma</b>	1.5	17	0.7	11
<b>Kaposi Sarcoma</b>	1.6	37	0.4	7
<b>Ill-Defined &amp; Unspecified Sites</b>	12.2	157	9.9	170

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\*\* Non-applicable gender.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 8. Comparative Incidence Rates, New Jersey and U.S., 1999-2003  
Males**

<b>Cancer Site</b>	<b>New Jersey 1999-2003</b>			<b>United States 1999-2003</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	623.9	619.2	694.7	562.1	555.0	639.8
<b>Colorectal</b>	73.1	72.9	78.7	64.2	63.8	70.2
<b>Lung</b>	85.0	84.2	104.0	89.6	88.8	110.6
<b>Prostate</b>	200.3	189.4	287.6	165.0	156.0	243.0
<b>Melanoma</b>	22.9	26.3	0.8	20.5	22.5	1.1
<b>Thyroid</b>	5.2	5.5	3.0	4.1	4.3	2.3
<b>Non-Hodgkin Lymphoma</b>	25.7	26.1	19.9	22.6	23.1	16.6

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 9. Comparative Incidence Rates, New Jersey and U.S., 1999-2003  
Females**

<b>Cancer Site</b>	<b>New Jersey 1999-2003</b>			<b>United States 1999-2003</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	448.7	460.6	403.3	415.3	421.1	383.8
<b>Colorectal</b>	52.3	57.8	56.6	46.7	45.9	53.5
<b>Lung</b>	55.7	57.7	50.9	54.7	56.2	50.3
<b>Breast (invasive)</b>	133.9	138.4	113.3	128.2	130.8	111.5
<b>Endometrial (Corpus Uteri)</b>	27.7	29.2	21.2	23.0	23.8	18.3
<b>Melanoma</b>	14.2	16.9	0.9	13.1	14.8	0.9
<b>Thyroid</b>	14.8	15.8	8.4	11.6	12.0	7.2
<b>Non-Hodgkin Lymphoma</b>	18.0	18.7	12.8	16.0	16.5	11.1

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

Page intentionally blank

**Table 10. Age-adjusted Mortality Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>All Sites</b>	35,328	249.0	246.4	236.1	234.4
<b>Oral Cavity and Pharynx</b>	602	3.6	4.3	3.6	4.0
Lip	-	-	-	-	-
Tongue	163	1.0	1.0	0.9	1.2
Salivary Gland	60	0.3	0.4	0.6	0.4
Floor of Mouth	14	0.1	-	-	-
Gum and Other Mouth	64	0.2	0.4	0.4	0.5
Nasopharynx	61	0.5	0.5	-	0.4
Tonsil	44	0.1	0.5	0.2	0.2
Oropharynx	54	0.3	0.4	0.2	0.4
Hypopharynx	23	0.2	0.2	-	0.1
<b>Digestive System</b>	9,439	66.5	64.1	62.4	63.4
Esophagus	1,176	8.2	7.9	7.4	7.4
Stomach	1,082	7.4	7.4	7.5	7.2
Small Intestine	81	0.5	0.5	0.5	0.6
Colon and Rectum	3,867	28.4	26.4	26.4	25.7
Colon excluding Rectum	3,231	23.5	22.3	21.9	21.8
Rectum and Rectosigmoid Junction	636	4.9	4.1	4.5	3.9
Anus	17	-	-	0.1	0.1
Liver and Intrahepatic Bile Duct	1,102	7.6	7.4	6.5	7.8
Liver	917	6.1	6.2	5.5	6.4
Intrahepatic Bile Duct	185	1.5	1.2	1.0	1.4
Gallbladder	84	0.4	0.7	0.5	0.7
Pancreas	1,853	12.7	12.5	12.3	12.7
<b>Respiratory System</b>	10,557	73.2	73.6	67.9	68.8
Larynx	357	1.9	2.6	2.4	2.5
Lung and Bronchus	10,115	70.8	70.5	64.9	65.7
<b>Bones and Joints</b>	55	0.4	0.5	0.2	0.3
<b>Soft Tissue (Including Heart)</b>	210	1.5	1.3	1.3	1.4
<b>Skin (Excluding Basal and Squamous)</b>	758	5.1	5.2	5.2	4.7
Melanoma of the Skin	596	4.0	4.1	4.0	3.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 10 (continued). Age-adjusted Mortality Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>Breast</b>	69	0.5	0.4	0.6	0.4
<b>Male Genital System</b>	3,824	30.0	30.4	26.2	26.9
Prostate	3,754	29.5	30.1	25.9	26.3
Testis	39	0.2	0.2	0.2	0.3
Penis	27	0.2	0.1	-	0.2
<b>Urinary System</b>	2,102	15.5	14.4	15.6	13.5
Urinary Bladder	1,141	9.3	8.1	8.2	7.3
Kidney and Renal Pelvis	909	5.8	5.9	7.0	5.9
Ureter	22	0.2	0.2	0.2	-
<b>Eye</b>	8	-	-	-	-
<b>Brain and Other Nervous System</b>	733	4.9	4.6	4.5	4.6
<b>Endocrine System</b>	139	1.0	1.0	0.9	0.8
Thyroid	79	0.5	0.7	0.4	0.4
<b>Lymphomas</b>	1,625	11.6	10.5	11.1	10.6
Hodgkin Lymphoma	89	0.6	0.5	0.6	0.5
Non-Hodgkin Lymphoma	1,536	11.0	10.0	10.5	10.1
<b>Multiple Myeloma</b>	696	4.7	5.1	4.6	4.8
<b>Leukemias</b>	1,432	9.9	8.6	10.5	10.0
Lymphocytic Leukemia	411	2.7	2.3	3.2	3.2
Acute Lymphocytic Leukemia	90	0.5	0.5	0.7	0.6
Chronic Lymphocytic Leukemia	287	2.0	1.6	2.3	2.3
Myeloid and Monocytic Leukemia	629	4.0	3.6	4.8	4.3
Acute Myeloid Leukemia	487	3.0	2.6	3.7	3.7
Acute Monocytic Leukemia	6	-	0.0	-	-
Chronic Myeloid Leukemia	105	0.9	0.7	0.8	0.5
Other Leukemia	392	3.2	2.7	2.5	2.5
<b>Ill-Defined &amp; Unspecified Sites</b>	3,079	20.6	22.3	21.5	20.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 11. Age-adjusted Mortality Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>All Sites</b>	36,692	178.0	176.7	172.0	170.2
<b>Oral Cavity and Pharynx</b>	309	1.3	1.6	1.5	1.4
Lip	-	-	-	-	-
Tongue	91	0.4	0.6	0.4	0.4
Salivary Gland	25	0.1	0.1	0.1	0.1
Floor of Mouth	5	-	-	-	-
Gum and Other Mouth	60	0.2	0.3	0.3	0.3
Nasopharynx	28	-	0.1	0.2	0.1
Tonsil	16	0.1	-	-	-
Oropharynx	23	0.1	0.1	0.1	0.1
Hypopharynx	8	-	-	-	-
<b>Digestive System</b>	8,643	40.5	40.7	38.7	39.3
Esophagus	390	1.9	1.8	2.0	1.8
Stomach	751	3.7	3.5	3.5	3.3
Small Intestine	66	0.3	0.3	0.3	0.3
Colon and Rectum	4,154	19.1	19.6	17.9	19.0
Colon excluding Rectum	3,605	16.4	17.1	15.3	16.5
Rectum and Rectosigmoid Junction	549	2.7	2.5	2.5	2.5
Anus	31	-	0.1	0.1	0.3
Liver and Intrahepatic Bile Duct	613	2.9	3.1	2.5	3.0
Liver	406	1.8	2.2	1.6	1.9
Intrahepatic Bile Duct	207	1.1	0.9	0.9	1.1
Gallbladder	204	1.0	0.9	0.9	1.0
Pancreas	2,183	10.3	10.3	10.3	9.6
<b>Respiratory System</b>	8,605	42.0	41.6	41.5	41.3
Larynx	103	0.5	0.6	0.5	0.4
Lung and Bronchus	8,471	41.3	40.7	40.8	40.9
<b>Bones and Joints</b>	54	0.3	0.3	0.2	0.3
<b>Soft Tissue (Including Heart)</b>	259	1.5	1.3	1.3	1.1
<b>Skin (Excluding Basal and Squamous)</b>	423	1.9	2.1	2.0	2.0
Melanoma of the Skin	346	1.5	1.8	1.7	1.7
<b>Breast</b>	6,016	30.9	28.7	28.4	28.5

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 11 (continued). Age-adjusted Mortality Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>Female Genital System</b>	3,882	18.6	19.5	18.7	18.4
Cervix Uteri	534	2.8	3.1	2.4	2.7
Corpus and Uterus, NOS	1,098	5.1	5.5	5.3	5.0
Corpus Uteri	463	2.1	2.1	2.5	2.1
Uterus, NOS	635	3.0	3.5	2.7	2.9
Ovary	2,037	9.6	10.0	10.1	9.7
Vagina	34	0.1	0.2	0.1	0.2
Vulva	122	0.8	0.5	0.5	0.4
<b>Urinary System</b>	1,241	5.6	5.8	5.9	5.6
Urinary Bladder	611	2.6	2.9	2.8	2.6
Kidney and Renal Pelvis	589	2.8	2.8	2.8	2.7
Ureter	25	0.1	-	0.2	0.2
<b>Eye</b>	18	-	-	0.1	0.1
<b>Brain and Other Nervous System</b>	568	3.0	3.0	2.9	2.5
<b>Endocrine System</b>	156	0.8	0.8	0.6	0.8
Thyroid	106	0.5	0.5	0.4	0.5
<b>Lymphomas</b>	1,477	7.4	7.3	6.8	6.2
Hodgkin Lymphoma	98	0.6	0.5	0.5	0.5
Non-Hodgkin Lymphoma	1,379	6.8	6.8	6.3	5.7
<b>Multiple Myeloma</b>	720	3.5	3.5	3.1	3.3
<b>Leukemias</b>	1,221	5.5	5.8	6.0	5.7
Lymphocytic Leukemia	329	1.3	1.5	1.6	1.6
Acute Lymphocytic Leukemia	66	0.3	0.3	0.4	0.4
Chronic Lymphocytic Leukemia	242	0.9	1.1	1.1	1.1
Myeloid and Monocytic Leukemia	536	2.5	2.6	2.6	2.7
Acute Myeloid Leukemia	426	1.8	1.9	2.2	2.3
Acute Monocytic Leukemia	8	-	-	-	-
Chronic Myeloid Leukemia	82	0.6	0.5	0.3	0.2
Other Leukemia	356	1.6	1.6	1.8	1.4
<b>Ill-Defined &amp; Unspecified Sites</b>	3,100	15.1	14.7	14.3	13.6

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 12. Age-adjusted Mortality Rates, White Males**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>All Sites</b>	30,324	244.3	242.7	233.8	232.9
<b>Oral Cavity and Pharynx</b>	466	3.0	4.0	3.2	3.9
Lip	-	-	-	-	-
Tongue	134	0.8	1.1	0.8	1.3
Salivary Gland	55	0.3	0.3	0.6	0.4
Floor of Mouth	9	-	-	-	-
Gum and Other Mouth	48	0.2	0.4	0.4	0.4
Nasopharynx	41	0.4	0.4	-	0.4
Tonsil	33	0.1	0.4	0.2	0.3
Oropharynx	40	0.2	0.4	0.2	0.4
Hypopharynx	15	-	0.2	-	-
<b>Digestive System</b>	8,022	65.0	62.8	61.1	62.5
Esophagus	998	8.2	7.5	7.6	7.3
Stomach	871	7.1	6.7	6.8	6.7
Small Intestine	62	0.4	0.5	0.5	0.5
Colon and Rectum	3,355	27.9	26.4	26.3	25.8
Colon excluding Rectum	2,781	22.7	22.2	21.6	21.9
Rectum and Rectosigmoid Junction	574	5.2	4.1	4.7	3.9
Anus	16	-	-	0.2	-
Liver and Intrahepatic Bile Duct	869	6.9	6.8	6.0	7.2
Liver	703	5.5	5.7	4.9	5.7
Intrahepatic Bile Duct	166	1.5	1.2	1.1	1.4
Gallbladder	72	0.4	0.7	0.4	0.7
Pancreas	1,623	12.7	12.7	12.4	12.9
<b>Respiratory System</b>	9,027	71.7	72.1	67.3	68.3
Larynx	261	1.6	2.1	2.1	2.2
Lung and Bronchus	8,692	69.7	69.4	64.6	65.5
<b>Bones and Joints</b>	49	0.5	0.5	0.2	0.4
<b>Soft Tissue (Including Heart)</b>	183	1.6	1.3	1.2	1.5
<b>Skin (Excluding Basal and Squamous)</b>	733	5.5	5.9	6.0	5.3
Melanoma of the Skin	587	4.5	4.8	4.6	4.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.



**Table 12 (continued). Age-adjusted Mortality Rates, White Males**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>Breast</b>	60	0.4	0.5	0.5	0.4
<b>Male Genital System</b>	3,100	27.0	27.5	24.1	24.7
Prostate	3,037	26.5	27.1	23.7	24.2
Testis	38	0.3	0.2	0.3	0.3
Penis	23	0.2	0.1	-	0.2
<b>Urinary System</b>	1,925	16.1	14.9	16.4	14.2
Urinary Bladder	1,073	9.7	8.6	8.8	7.9
Kidney and Renal Pelvis	807	6.1	6.0	7.2	5.9
Ureter	21	0.2	-	0.2	-
<b>Eye</b>	8	-	-	-	-
<b>Brain and Other Nervous System</b>	677	5.4	5.1	4.8	5.1
<b>Endocrine System</b>	117	0.9	1.1	0.7	0.8
Thyroid	72	0.6	0.7	0.4	0.5
<b>Lymphomas</b>	1,453	12.0	11.0	11.3	11.2
Hodgkin Lymphoma	80	0.7	0.6	0.7	0.6
Non-Hodgkin Lymphoma	1,373	11.3	10.4	10.7	10.6
<b>Multiple Myeloma</b>	567	4.4	4.8	4.5	4.2
<b>Leukemias</b>	1,274	10.2	8.9	10.7	10.4
Lymphocytic Leukemia	373	2.9	2.4	3.3	3.4
Acute Lymphocytic Leukemia	77	0.5	0.5	0.8	0.6
Chronic Lymphocytic Leukemia	265	2.1	1.6	2.3	2.5
Myeloid and Monocytic Leukemia	552	4.0	3.8	4.9	4.4
Acute Myeloid Leukemia	433	3.0	2.7	4.0	3.7
Acute Monocytic Leukemia	5	-	0.0	0.0	-
Chronic Myeloid Leukemia	84	0.8	0.8	0.6	0.5
Other Leukemia	349	3.3	2.7	2.5	2.7
<b>Ill-Defined and Unspecified Sites</b>	2,663	20.3	22.2	21.6	19.8

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 13. Age-adjusted Mortality Rates, White Females**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>All Sites</b>	31,923	179.0	178.1	173.0	171.2
<b>Oral Cavity and Pharynx</b>	257	1.3	1.6	1.4	1.2
Lip	-	-	-	-	-
Tongue	76	0.4	0.6	0.4	0.3
Salivary Gland	23	0.2	0.2	0.1	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	55	0.2	0.3	0.3	0.3
Nasopharynx	16	-	-	0.1	-
Tonsil	13	0.1	-	-	-
Oropharynx	21	0.1	0.1	0.1	0.1
Hypopharynx	7	-	-	-	-
<b>Digestive System</b>	7,423	40.0	39.1	38.2	38.6
Esophagus	323	1.8	1.5	2.0	1.7
Stomach	603	3.4	2.9	3.3	3.1
Small Intestine	56	0.2	0.3	0.3	0.3
Colon and Rectum	3,620	19.1	19.5	17.8	18.5
Colon excluding Rectum	3,126	16.2	17.0	15.1	16.0
Rectum and Rectosigmoid Junction	494	2.9	2.5	2.6	2.5
Anus	28	-	0.1	0.1	0.3
Liver and Intrahepatic Bile Duct	512	2.7	2.7	2.5	3.0
Liver	339	1.7	1.9	1.6	1.9
Intrahepatic Bile Duct	173	1.0	0.8	0.9	1.1
Gallbladder	173	1.0	0.9	0.9	1.0
Pancreas	1,886	10.3	10.1	10.2	9.6
<b>Respiratory System</b>	7,616	43.4	43.0	42.7	42.2
Larynx	84	0.5	0.7	0.5	0.3
Lung and Bronchus	7,504	42.8	42.0	42.0	41.8
<b>Bones and Joints</b>	47	0.3	0.3	0.3	0.3
<b>Soft Tissue (Including Heart)</b>	212	1.5	1.2	1.1	1.2
<b>Skin (Excluding Basal and Squamous)</b>	404	2.0	2.4	2.2	2.3
Melanoma of the Skin	334	1.6	2.1	1.9	2.0
<b>Breast</b>	5,128	30.8	28.7	28.1	28.5

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 13 (continued). Age-adjusted Mortality Rates, White Females**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>Female Genital System</b>	3,313	18.4	20.0	18.4	18.2
Cervix Uteri	394	2.4	3.1	2.0	2.3
Corpus and Uterus, NOS	919	4.8	5.7	5.0	4.8
Corpus Uteri	399	2.0	2.3	2.5	2.1
Uterus, NOS	520	2.8	3.4	2.5	2.7
Ovary	1,809	9.9	10.3	10.4	10.3
Vagina	28	-	0.2	0.1	0.2
Vulva	114	0.8	0.5	0.6	0.4
<b>Urinary System</b>	1,114	5.6	6.0	6.0	5.8
Urinary Bladder	542	2.7	2.8	2.8	2.6
Kidney and Renal Pelvis	536	2.8	3.0	3.0	3.0
Ureter	24	0.1	-	0.2	0.2
<b>Eye</b>	17	-	-	0.1	0.1
<b>Brain and Other Nervous System</b>	524	3.3	3.3	3.2	2.7
<b>Endocrine System</b>	137	0.9	0.8	0.7	0.8
Thyroid	95	0.6	0.6	0.4	0.5
<b>Lymphomas</b>	1,350	7.8	7.7	7.2	6.4
Hodgkin Lymphoma	90	0.6	0.6	0.6	0.5
Non-Hodgkin Lymphoma	1,260	7.2	7.1	6.6	5.9
<b>Multiple Myeloma</b>	577	3.3	3.2	2.8	3.0
<b>Leukemias</b>	1,105	5.6	6.1	6.4	6.0
Lymphocytic Leukemia	303	1.4	1.7	1.7	1.7
Acute Lymphocytic Leukemia	63	0.3	0.4	0.4	0.5
Chronic Lymphocytic Leukemia	222	0.9	1.1	1.2	1.1
Myeloid and Monocytic Leukemia	484	2.5	2.8	2.7	2.9
Acute Myeloid Leukemia	387	1.8	2.1	2.3	2.5
Acute Monocytic Leukemia	7	-	-	-	-
Chronic Myeloid Leukemia	74	0.6	0.5	0.3	0.2
Other Leukemia	318	1.7	1.7	1.9	1.4
<b>Ill-Defined &amp; Unspecified Sites</b>	2,699	14.8	14.6	14.3	13.8

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 14. Age-adjusted Mortality Rates, Black Males**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>All Sites</b>	4,391	346.4	329.6	298.1	310.4
<b>Oral Cavity and Pharynx</b>	116	9.5	7.3	6.9	5.2
Lip	-	-	-	-	-
Tongue	27	3.8	-	1.9	-
Salivary Gland	-	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	16	-	-	-	1.7
Nasopharynx	12	1.6	-	-	-
Tonsil	11	-	1.3	-	-
Oropharynx	13	-	-	-	-
Hypopharynx	7	-	-	-	-
<b>Digestive System</b>	1,193	90.1	84.4	77.8	83.5
Esophagus	163	11.0	12.8	8.7	10.7
Stomach	173	12.6	13.3	15.0	11.3
Small Intestine	18	2.1	-	-	1.2
Colon and Rectum	453	37.0	31.9	28.7	32.5
Colon excluding Rectum	402	35.0	29.0	26.1	27.2
Rectum and Rectosigmoid Junction	51	2.0	2.9	2.6	5.3
Anus	-	0.0	0.0	0.0	-
Liver and Intrahepatic Bile Duct	167	9.8	12.4	8.2	12.3
Liver	153	8.9	11.3	7.8	11.5
Intrahepatic Bile Duct	14	-	1.1	-	-
Gallbladder	5	-	-	-	-
Pancreas	196	15.8	12.2	13.2	14.8
<b>Respiratory System</b>	1,374	102.5	102.0	86.3	93.7
Larynx	86	4.8	7.0	5.5	5.9
Lung and Bronchus	1,278	96.9	95.0	80.2	86.7
<b>Bones and Joints</b>	5	-	-	-	-
<b>Soft Tissue (Including Heart)</b>	24	1.2	1.6	1.7	1.2
<b>Skin (Excluding Basal and Squamous)</b>	19	1.9	-	-	-
Melanoma of the Skin	6	-	-	-	-

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 14 (continued). Age-adjusted Mortality Rates, Black Males**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>Breast</b>	8	-	-	-	-
<b>Male Genital System</b>	691	70.8	69.2	57.9	60.1
Prostate	687	70.3	69.2	57.9	59.3
Testis	-	-	-	-	-
Penis	-	-	-	-	-
<b>Urinary System</b>	148	11.7	10.9	11.5	9.9
Urinary Bladder	56	6.8	4.8	4.3	2.6
Kidney and Renal Pelvis	85	3.8	5.9	6.7	7.0
Ureter	-	-	-	-	-
<b>Eye</b>	-	-	-	-	-
<b>Brain and Other Nervous System</b>	41	2.3	1.5	2.4	2.9
<b>Endocrine System</b>	17	1.0	-	1.5	-
Thyroid	6	-	-	-	-
<b>Lymphomas</b>	145	10.1	6.8	10.3	6.8
Hodgkin Lymphoma	5	-	-	-	-
Non-Hodgkin Lymphoma	140	9.8	6.7	10.3	6.5
<b>Multiple Myeloma</b>	115	7.2	8.9	6.2	10.6
<b>Leukemias</b>	129	8.5	7.0	10.6	8.5
Lymphocytic Leukemia	34	1.4	2.0	3.5	2.7
Acute Lymphocytic Leukemia	10	-	-	-	-
Chronic Lymphocytic Leukemia	21	-	1.4	2.7	1.6
Myeloid and Monocytic Leukemia	59	4.7	2.7	4.7	3.4
Acute Myeloid Leukemia	41	3.0	2.4	2.0	2.9
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	16	-	-	2.3	-
Other Leukemia	36	2.4	2.4	2.5	2.4
<b>Ill-Defined &amp; Unspecified Sites</b>	366	28.5	28.3	23.2	26.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 15. Age-adjusted Mortality Rates, Black Females**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>All Sites</b>	4,192	195.7	190.9	196.8	192.4
<b>Oral Cavity and Pharynx</b>	42	1.7	1.7	1.8	2.8
Lip	-	-	-	-	-
Tongue	10	-	-	-	-
Salivary Gland	-	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	-	-	-	-	-
Nasopharynx	9	-	-	-	-
Tonsil	-	-	-	-	-
Oropharynx	-	-	-	-	-
Hypopharynx	-	-	-	-	-
<b>Digestive System</b>	1,049	46.9	54.4	49.6	50.1
Esophagus	57	2.5	3.6	2.2	2.3
Stomach	114	4.6	6.1	6.0	5.1
Small Intestine	9	-	-	-	-
Colon and Rectum	488	22.0	22.8	23.0	25.9
Colon excluding Rectum	444	20.5	20.2	20.7	23.6
Rectum and Rectosigmoid Junction	44	1.5	2.6	2.2	2.3
Anus	-	-	-	-	-
Liver and Intrahepatic Bile Duct	67	2.9	4.9	2.3	2.3
Liver	45	1.5	3.7	1.5	1.8
Intrahepatic Bile Duct	22	1.4	1.2	-	-
Gallbladder	27	-	1.3	1.8	1.1
Pancreas	262	12.6	13.5	12.6	12.2
<b>Respiratory System</b>	896	39.8	39.8	42.4	42.4
Larynx	19	0.9	-	1.1	1.1
Lung and Bronchus	875	38.8	39.7	41.3	41.1
<b>Bones and Joints</b>	7	-	-	-	-
<b>Soft Tissue (Including Heart)</b>	44	1.8	1.6	2.5	1.3
<b>Skin (Excluding Basal and Squamous)</b>	14	-	-	-	-
Melanoma of the Skin	8	-	-	-	-
<b>Breast</b>	787	37.8	31.6	36.1	34.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 15 (continued). Age-adjusted Mortality Rates, Black Females**

Cancer Site	Total Cases	Rates			
		2000	2001	2002	2003
<b>Female Genital System</b>	496	23.2	19.5	24.5	23.2
Cervix Uteri	123	5.4	4.4	5.2	6.5
Corpus and Uterus, NOS	164	8.1	6.0	9.1	8.0
Corpus Uteri	58	2.8	1.1	4.1	3.2
Uterus, NOS	106	5.3	4.9	5.1	4.8
Ovary	188	8.8	8.5	9.4	7.6
Vagina	6	-	-	-	-
Vulva	7	-	-	-	-
<b>Urinary System</b>	116	5.8	5.2	6.9	4.6
Urinary Bladder	65	2.5	3.3	3.8	3.2
Kidney and Renal Pelvis	47	3.2	2.0	2.9	1.0
Ureter	-	-	-	-	-
<b>Eye</b>	-	-	-	-	-
<b>Brain and Other Nervous System</b>	33	1.8	1.5	1.3	1.4
<b>Endocrine System</b>	11	0.8	-	-	-
Thyroid	6	-	-	-	-
<b>Lymphomas</b>	98	4.9	4.5	3.9	4.0
Hodgkin Lymphoma	8	-	-	-	-
Non-Hodgkin Lymphoma	90	4.3	4.4	3.8	3.7
<b>Multiple Myeloma</b>	138	6.2	7.0	6.1	7.5
<b>Leukemias</b>	97	5.1	4.5	4.0	4.4
Lymphocytic Leukemia	24	1.7	-	1.1	1.2
Acute Lymphocytic Leukemia	-	-	-	-	-
Chronic Lymphocytic Leukemia	19	1.3	-	-	1.2
Myeloid and Monocytic Leukemia	38	2.1	1.6	1.3	1.8
Acute Myeloid Leukemia	28	1.6	-	1.0	1.6
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	5	-	-	-	-
Other Leukemia	35	1.3	2.1	1.7	1.4
<b>Ill-Defined &amp; Unspecified Sites</b>	363	19.0	18.1	16.4	14.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 16. Age-adjusted Mortality Rates, Hispanic Males and Females  
2000-2003 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	151.1	1,520	93.2	1,323
<b>Oral Cavity and Pharynx</b>	3.2	39	1.1	15
Lip	-	-	-	-
Tongue	0.9	14	-	-
Salivary Gland	-	-	-	-
Floor of Mouth	-	-	-	-
Gum and Other Mouth	-	-	-	-
Nasopharynx	-	-	-	-
Tonsil	0.4	6	-	-
Oropharynx	0.6	6	-	-
Hypopharynx	-	-	-	-
<b>Digestive System</b>	47.1	495	27.1	361
Esophagus	4.2	48	1.3	15
Stomach	7.7	87	2.9	44
Small Intestine	0.4	5	-	-
Colon and Rectum	18.6	179	11.2	148
Colon excluding Rectum	16.2	155	9.8	127
Rectum and Rectosigmoid Junction	2.4	24	1.4	21
Anus	-	-	-	-
Liver and Intrahepatic Bile Duct	7.4	84	3.5	45
Liver	6.4	74	2.9	37
Intrahepatic Bile Duct	0.9	10	0.6	8
Gallbladder	0.8	7	1.7	24
Pancreas	7.2	77	6.0	78
<b>Respiratory System</b>	35.2	362	13.0	168
Larynx	2.0	22	-	-
Lung and Bronchus	32.9	337	13.0	167
<b>Bones and Joints</b>	-	-	-	-
<b>Soft Tissue (Including Heart)</b>	0.8	11	0.4	8
<b>Skin (Excluding Basal and Squamous)</b>	0.9	13	0.4	7
Melanoma of the Skin	0.4	7	0.4	7
<b>Breast</b>	-	-	15.1	243

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.



**Table 16 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females  
2000-2003 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	**	**	11.6	172
Cervix Uteri	**	**	2.8	51
Corpus and Uterus, NOS	**	**	3.5	48
Corpus Uteri	**	**	1.5	20
Uterus, NOS	**	**	2.0	28
Ovary	**	**	4.4	63
Vagina	**	**	-	-
Vulva	**	**	0.5	5
<b>Male Genital System</b>	21.4	157	**	**
Prostate	21.0	148	**	**
Testis	-	-	**	**
Penis	0.3	6	**	**
<b>Urinary System</b>	8.2	68	2.3	31
Urinary Bladder	4.8	34	1.2	16
Kidney and Renal Pelvis	3.1	32	1.1	15
Ureter	-	-	-	-
<b>Eye</b>	-	-	-	-
<b>Brain and Other Nervous System</b>	2.5	31	1.0	19
<b>Endocrine System</b>	0.4	7	0.8	12
Thyroid	-	-	0.5	6
<b>Lymphomas</b>	8.3	87	4.1	62
Hodgkin Lymphoma	0.4	6	0.3	6
Non-Hodgkin Lymphoma	7.9	81	3.8	56
<b>Multiple Myeloma</b>	4.1	34	3.0	38
<b>Leukemias</b>	4.6	68	4.2	67
Lymphocytic Leukemia	1.0	18	0.8	13
Acute Lymphocytic Leukemia	0.5	14	0.5	10
Chronic Lymphocytic Leukemia	-	-	-	-
Myeloid and Monocytic Leukemia	2.4	33	1.9	33
Acute Myeloid Leukemia	1.9	25	1.4	24
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	0.5	7	0.4	7
Other Leukemia	1.1	17	1.5	21
<b>Ill-Defined &amp; Unspecified Sites</b>	14.0	142	8.8	116

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

\*\* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17. Comparative Mortality Rates, New Jersey and U.S., 1999-2003**  
**Males**

<b>Cancer Site</b>	<b>New Jersey 1999-2003</b>			<b>United States 1999-2003</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	244.5	241.2	323.6	243.7	239.2	331.0
<b>Lung</b>	68.7	68.1	90.0	74.8	73.8	98.4
<b>Prostate</b>	28.4	26.0	63.2	29.1	26.7	65.1
<b>Colorectal</b>	27.1	27.0	32.4	24.3	23.7	33.6

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

**Table 18. Comparative Mortality Rates, New Jersey and U.S., 1999-2003**  
**Females**

<b>Cancer Site</b>	<b>New Jersey 1999-2003</b>			<b>United States 1999-2003</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	175.0	176.1	194.9	164.3	163.4	192.4
<b>Lung</b>	40.7	41.8	40.4	41.0	42.0	39.8
<b>Breast</b>	29.1	29.0	34.4	26.0	25.4	34.4
<b>Colorectal</b>	19.1	18.9	23.2	17.0	16.4	23.7

Source-NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard)

***Cancer Incidence and Mortality in New Jersey, 2000-2004***

**Table 19. Population Denominators**

	1999						2000					
	All Races	All Races	White	White	Black	Black	All Races	All Races	White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	56,197	53,956	42,042	40,260	9,910	9,641	56,449	54,192	42,023	40,284	10,033	9,753
01-04	231,265	221,158	173,397	165,299	41,287	39,533	230,961	220,927	172,512	164,230	41,040	39,550
05-09	309,684	295,052	232,333	220,962	57,043	54,943	308,948	294,379	230,545	219,291	57,102	54,893
10-14	294,507	280,131	222,127	210,858	53,153	51,437	304,917	290,079	229,718	217,977	55,109	53,481
15-19	269,267	252,487	202,095	187,761	49,142	47,814	274,224	256,920	205,669	191,194	49,708	48,228
20-24	243,493	234,381	182,461	171,854	43,430	44,790	244,700	235,096	182,744	171,353	43,893	45,329
25-29	274,458	274,353	205,803	201,011	44,775	48,643	270,589	269,446	201,406	195,502	43,593	47,882
30-34	325,341	331,258	252,770	249,456	48,809	54,912	318,148	324,024	243,207	242,597	47,777	53,769
35-39	362,946	370,291	287,608	287,859	50,519	56,716	360,491	367,651	283,014	284,011	50,625	56,696
40-44	343,088	354,841	276,591	280,256	43,413	50,334	349,835	360,908	280,602	284,152	44,722	51,457
45-49	291,544	307,297	238,700	245,709	34,346	42,147	300,105	315,789	245,173	252,461	35,284	42,859
50-54	256,150	276,145	212,492	224,316	28,355	35,929	265,384	286,399	219,402	231,502	29,738	37,704
55-59	197,560	215,229	164,332	175,638	22,454	28,751	204,112	222,389	169,546	181,380	23,011	29,280
60-64	154,981	173,309	128,537	141,767	18,376	23,705	156,730	175,186	129,301	142,574	18,727	24,162
65-69	133,493	161,967	114,537	136,884	14,099	19,161	131,867	159,657	112,453	134,090	14,146	19,262
70-74	121,915	161,468	108,283	142,034	10,470	15,057	121,380	159,382	107,340	139,395	10,703	15,355
75-79	94,572	143,041	85,790	128,649	6,799	11,515	95,984	144,846	86,796	129,957	7,038	11,743
80-84	57,365	102,699	52,939	93,898	3,431	7,210	59,060	104,850	54,311	95,620	3,639	7,466
85+	37,495	95,208	34,542	87,341	2,367	6,826	39,376	98,324	36,199	89,975	2,503	7,163
Total	4,055,321	4,304,271	3,217,379	3,391,812	582,178	649,064	4,093,260	4,340,444	3,231,961	3,407,545	588,391	656,032

  

	2001						2002					
	All Races	All Races	White	White	Black	Black	All Races	All Races	White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	57,984	55,893	41,744	40,169	11,510	11,322	58,245	56,130	42,164	40,438	11,429	11,092
01-04	229,331	219,536	171,036	162,964	40,451	39,249	229,531	220,141	169,453	161,985	41,680	40,453
05-09	306,960	292,909	228,524	217,774	56,150	53,753	303,662	289,735	225,835	214,894	54,685	52,377
10-14	312,147	297,216	234,656	222,720	56,539	54,972	316,879	301,549	237,298	225,074	57,563	55,914
15-19	283,427	266,363	213,101	198,801	50,632	49,186	288,463	274,274	216,875	205,038	51,343	50,340
20-24	246,754	235,285	182,924	170,913	45,244	45,914	252,640	238,048	186,695	172,918	46,531	46,465
25-29	261,180	257,681	192,980	185,140	41,931	45,605	256,941	251,687	189,183	179,921	41,338	44,374
30-34	315,386	320,575	238,622	237,544	47,381	53,283	311,964	315,322	233,006	230,505	47,097	52,633
35-39	357,199	364,443	278,342	278,889	50,531	57,140	351,459	359,905	271,673	273,341	50,084	56,706
40-44	357,226	367,263	285,394	288,263	46,166	52,606	361,856	370,453	288,048	289,319	47,066	53,683
45-49	309,408	324,113	251,904	258,240	36,484	43,919	321,084	335,117	260,100	266,193	38,386	45,353
50-54	275,648	297,167	227,316	239,448	31,021	39,495	273,489	294,376	223,839	235,476	31,425	39,920
55-59	209,830	228,922	174,119	186,674	23,250	29,495	226,264	246,440	188,618	201,493	24,235	30,932
60-64	159,584	179,033	131,400	145,168	18,905	24,664	165,703	186,129	136,341	150,632	19,258	25,399
65-69	129,685	156,168	109,337	129,617	14,345	19,755	128,824	154,817	107,902	127,591	14,231	19,864
70-74	119,718	156,983	105,492	136,493	10,623	15,469	116,926	153,445	102,109	132,278	10,786	15,689
75-79	96,453	144,343	86,696	128,734	7,347	12,139	96,902	143,703	86,846	127,494	7,422	12,397
80-84	62,266	108,132	57,090	98,406	3,899	7,770	64,483	110,106	58,869	99,926	4,170	7,995
85+	41,414	101,239	37,998	92,579	2,622	7,282	44,115	105,282	40,409	96,142	2,763	7,518
Total	4,131,600	4,373,264	3,248,675	3,418,536	595,031	663,018	4,169,430	4,406,659	3,265,263	3,430,658	601,492	669,104

  

	2003						2004					
	All Races	All Races	White	White	Black	Black	All Races	All Races	White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
<1	59,116	56,822	42,644	40,825	11,426	11,128	58,882	56,664	42,466	40,771	11,296	10,998
01-04	231,739	222,511	169,871	162,461	43,013	41,819	234,832	226,042	170,801	163,926	44,379	43,161
05-09	301,155	287,747	223,821	213,210	53,547	51,253	299,131	285,912	222,504	211,496	52,429	50,441
10-14	320,048	304,921	238,981	226,805	58,144	56,667	320,783	305,766	238,722	226,933	58,349	56,565
15-19	293,665	279,885	220,740	209,404	52,184	51,068	300,807	286,813	225,879	214,305	53,470	52,504
20-24	260,456	245,145	192,243	178,185	47,884	47,707	266,690	251,078	197,073	183,440	48,633	47,778
25-29	255,153	247,041	187,529	176,504	41,413	43,564	254,488	244,046	186,283	173,621	42,307	43,940
30-34	305,811	307,812	226,113	222,198	46,141	51,573	297,088	297,766	217,333	212,571	44,913	49,979
35-39	344,039	352,015	264,047	265,078	49,151	55,741	335,061	341,838	255,182	255,119	47,749	54,067
40-44	363,819	371,908	287,823	288,920	47,864	54,325	365,056	372,639	286,735	287,279	48,592	55,421
45-49	331,164	344,442	267,066	272,200	40,054	47,124	338,102	351,668	271,591	276,834	41,131	48,362
50-54	276,296	297,486	225,388	237,366	31,689	40,258	282,299	301,650	229,766	240,388	32,527	40,575
55-59	232,438	253,387	192,836	205,891	25,025	32,025	239,768	262,368	198,450	212,365	25,737	33,355
60-64	175,521	196,263	145,274	159,422	19,570	26,038	180,699	202,699	149,817	164,694	19,672	26,408
65-69	129,368	154,153	107,595	126,232	14,410	20,057	131,715	156,256	108,933	127,347	14,719	20,438
70-74	113,983	150,143	98,788	128,280	10,754	15,999	109,254	144,769	93,780	122,331	10,630	16,150
75-79	97,122	143,102	86,609	126,324	7,619	12,601	96,946	139,802	86,096	122,674	7,669	12,609
80-84	65,923	111,924	59,952	101,098	4,352	8,377	68,250	115,415	61,862	103,862	4,558	8,869
85+	47,013	109,492	42,968	99,946	2,948	7,689	49,238	112,886	44,805	102,819	3,178	7,940
Total	4,203,829	4,436,199	3,280,288	3,440,349	607,188	675,013	4,229,089	4,456,077	3,288,078	3,442,775	611,938	679,560

Source: The National Cancer Institute's SEER Program.

***Cancer Incidence and Mortality in New Jersey, 2000-2004***

**Table 19. Population Denominators  
Hispanic Population, 2000-2004**

	Male Total	Male 2000	Male 2001	Male 2002	Male 2003	Male 2004	Female Total	Female 2000	Female 2001	Female 2002	Female 2003	Female 2004
<1	63,455	10,848	12,086	12,748	13,728	14,045	60,688	10,339	11,670	12,114	13,088	13,477
00-04	221,724	40,041	41,195	43,595	46,580	50,313	211,803	38,394	39,287	41,684	44,464	47,974
05-09	257,481	50,060	50,785	51,422	52,326	52,888	245,992	47,670	48,725	49,094	49,886	50,617
10-14	249,213	46,438	48,177	50,066	51,599	52,933	239,447	44,822	46,492	48,200	49,431	50,502
15-19	242,372	48,417	48,490	47,995	48,333	49,137	224,395	43,375	43,819	44,509	45,824	46,868
20-24	293,771	56,392	58,137	59,776	60,213	59,253	244,353	47,380	48,411	49,348	49,831	49,383
25-29	303,059	56,940	58,622	60,350	62,584	64,563	256,079	49,912	50,352	51,043	51,873	52,899
30-34	294,720	55,746	57,521	59,025	60,556	61,872	267,911	51,576	52,980	53,790	54,490	55,075
35-39	283,078	52,751	55,394	57,092	58,564	59,277	267,676	50,506	52,650	54,111	55,155	55,254
40-44	239,733	42,022	44,892	48,076	50,999	53,744	235,094	42,407	44,726	46,847	49,599	51,515
45-49	179,760	31,377	33,696	36,009	38,349	40,329	186,944	33,084	35,044	37,587	39,589	41,640
50-54	137,071	24,829	26,187	27,403	28,549	30,103	148,404	27,239	28,525	29,542	30,801	32,297
55-59	102,112	17,894	18,996	20,470	21,747	23,005	114,865	20,105	21,616	23,084	24,407	25,653
60-64	75,781	13,880	14,575	15,184	15,864	16,278	87,581	15,810	16,681	17,486	18,389	19,215
65-69	52,856	9,575	9,934	10,441	11,064	11,842	65,910	12,092	12,563	13,230	13,700	14,325
70-74	36,447	6,612	7,083	7,331	7,614	7,807	49,926	8,948	9,563	10,065	10,510	10,840
75-79	23,905	3,859	4,316	4,809	5,233	5,688	35,501	6,073	6,571	7,074	7,631	8,152
80-84	12,733	1,988	2,210	2,529	2,840	3,166	22,103	3,702	4,049	4,404	4,795	5,153
85+	9,110	1,397	1,625	1,812	2,015	2,261	20,099	3,207	3,586	3,991	4,436	4,879
Total	3,078,381	571,066	593,921	616,133	638,757	658,504	2,984,771	556,641	577,310	597,203	617,899	635,718

Source: The National Cancer Institute's SEER Program.

**Table 20. Age Distribution (%) of Incidence Cases in New Jersey, 2000-2004  
All Races, Both Sexes**

Cancer Site	0-19	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.9%	2.3%	5.7%	12.8%	20.6%	26.1%	23.9%	7.7%	100%	230,761
Male	0.9%	1.9%	3.8%	10.8%	22.2%	30.0%	24.4%	6.1%	100%	118,261
Female	0.8%	2.9%	7.7%	14.9%	18.9%	22.0%	23.4%	9.4%	100%	112,500
Oral Cavity and Pharynx	0.3%	2.1%	7.4%	20.4%	24.0%	22.6%	17.4%	5.9%	100%	4,429
Esophagus	0.0%	0.3%	2.4%	12.4%	23.4%	29.5%	23.8%	8.2%	100%	2,286
Stomach	0.1%	1.4%	4.4%	9.1%	17.4%	26.0%	29.3%	12.3%	100%	4,115
Colon and Rectum	0.0%	0.8%	3.2%	9.4%	16.7%	25.4%	31.4%	12.9%	100%	26,739
Male	0.0%	0.8%	3.5%	10.3%	19.5%	27.9%	29.2%	8.8%	100%	13,259
Female	0.0%	0.8%	3.0%	8.6%	14.1%	23.0%	33.6%	16.9%	100%	13,480
Colon	0.0%	0.8%	2.7%	8.3%	15.3%	25.3%	33.3%	14.4%	100%	19,342
Rectum	0.0%	0.9%	4.6%	12.5%	20.6%	25.8%	26.6%	9.1%	100%	7,397
Liver and Intrahepatic Bile Duct	0.8%	1.1%	3.4%	16.8%	20.4%	24.8%	24.5%	8.1%	100%	2,621
Pancreas	0.0%	0.4%	2.4%	8.0%	17.7%	26.7%	31.9%	13.0%	100%	5,543
Lung and Bronchus	0.0%	0.2%	2.2%	8.5%	20.9%	31.4%	29.4%	7.3%	100%	29,847
Male	0.0%	0.2%	1.9%	8.2%	21.7%	32.7%	29.1%	6.1%	100%	15,659
Female	0.0%	0.2%	2.5%	8.8%	20.2%	30.0%	29.8%	8.5%	100%	14,188
Melanoma of the Skin	0.9%	6.1%	12.5%	16.8%	18.4%	20.9%	18.1%	6.3%	100%	8,418
Breast (female)	0.0%	1.9%	11.1%	21.8%	21.9%	20.0%	17.4%	5.9%	100%	32,550
Cervix Uteri	0.1%	12.8%	23.7%	24.7%	16.1%	11.5%	8.3%	2.9%	100%	2,257
Corpus and Uterus, NOS	0.0%	0.9%	4.9%	16.7%	29.2%	25.3%	17.9%	5.0%	100%	6,998
Ovary	0.8%	2.8%	8.5%	19.3%	21.7%	19.9%	19.4%	7.6%	100%	3,793
Prostate	0.0%	0.0%	0.6%	8.3%	27.0%	37.0%	23.0%	4.2%	100%	37,193
Testis	5.1%	44.0%	32.2%	13.3%	3.2%	1.0%	1.0%	0.2%	100%	1,249
Urinary Bladder	0.1%	0.5%	2.2%	7.6%	17.8%	28.7%	31.8%	11.4%	100%	11,810
Kidney and Renal Pelvis	1.4%	1.5%	6.1%	15.0%	22.2%	26.3%	22.1%	5.3%	100%	6,348
Brain and Other Nervous System	12.4%	7.7%	9.3%	15.5%	16.6%	18.2%	16.0%	4.3%	100%	3,099
Thyroid	1.9%	16.1%	22.3%	23.0%	16.8%	11.7%	6.8%	1.4%	100%	4,929
Hodgkin Lymphoma	10.7%	31.2%	18.3%	13.5%	10.2%	8.2%	6.2%	1.7%	100%	1,434
Non-Hodgkin Lymphoma	1.6%	3.8%	7.7%	13.9%	17.5%	22.3%	24.8%	8.5%	100%	9,555
Myeloma	0.0%	0.6%	3.0%	11.7%	18.0%	27.6%	29.1%	10.1%	100%	2,754
Leukemia	8.7%	4.1%	5.2%	10.0%	15.0%	21.1%	26.0%	9.9%	100%	5,758
Acute Lymphocytic Leukemia	57.5%	9.2%	5.6%	5.9%	5.6%	7.8%	6.7%	1.9%	100%	631
Chronic Lymphocytic Leukemia	0.1%	0.4%	2.0%	9.0%	19.6%	26.0%	31.3%	11.6%	100%	1,988
Acute Myeloid Leukemia	5.3%	6.1%	6.4%	10.5%	14.4%	21.7%	26.4%	9.2%	100%	1,748
Chronic Myeloid Leukemia	1.9%	5.4%	9.5%	13.9%	14.6%	20.6%	24.9%	9.3%	100%	686
Other Leukemia	5.0%	3.6%	3.9%	6.5%	8.9%	20.1%	32.3%	19.8%	100%	338
Mesothelioma	0.0%	0.3%	1.1%	4.3%	13.6%	28.4%	42.8%	9.5%	100%	715
Kaposi Sarcoma	0.0%	17.9%	22.8%	13.8%	7.5%	10.8%	18.3%	9.0%	100%	268

**Table 21. Median Age of Cancer Patients at Diagnosis, New Jersey 2000-2004  
By Primary Cancer Site, Race and Sex**

Cancer Site	All Races			Whites			Blacks		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	68	68	67	69	69	68	64	65	62
Oral Cavity and Pharynx	63	61	67	64	62	68	58	59	57
Esophagus	69	68	72	70	68	72	64	64	62
Stomach	72	70	74	73	71	76	68	67	71
Colon and Rectum	73	71	75	74	72	76	67	66	68
Colon excluding Rectum	74	72	75	75	73	76	68	67	69
Rectum	69	68	72	71	69	73	64	64	65
Liver and Intrahepatic Bile Duct	68	65	74	70	68	76	60	58	67
Pancreas	73	70	75	73	71	76	70	67	72
Lung and Bronchus	71	71	71	71	71	72	67	66	67
Melanoma of the Skin	62	64	58	62	64	58	68	62	70
Breast	61	69	61	62	70	62	58	62	58
Cervix Uteri	*	*	49	*	*	49	*	*	50
Corpus and Uterus, NOS	*	*	64	*	*	64	*	*	65
Ovary	*	*	63	*	*	64	*	*	61
Prostate	*	68	*	*	69	*	*	66	*
Testis	*	35	*	*	35	*	*	34	*
Urinary Bladder	73	72	74	73	72	74	70	68	72
Kidney and Renal Pelvis	66	65	68	67	65	69	62	61	64
Brain and Other Nervous System	58	57	59	59	58	60	50	47	52
Thyroid	48	53	47	49	54	47	50	53	49
Lymphoma	65	62	67	67	64	69	51	50	53
Hodgkin Lymphoma	39	40	38	39	40	38	41	40	41
Non-Hodgkin Lymphoma	67	65	69	69	67	71	53	52	56
Myeloma	71	70	72	72	71	74	67	67	68
Leukemia	68	67	70	70	69	72	59	59	61
Acute Lymphocytic Leukemia	15	15	14	16	16	15	13	12	17
Chronic Lymphocytic Leukemia	72	71	74	73	71	75	68	67	68
Acute Myeloid Leukemia	69	68	69	70	70	71	58	60	56
Chronic Myeloid Leukemia	67	68	67	70	70	70	58	58	55
Other Leukemia	75	73	77	76	74	79	61	49	75
Mesothelioma	75	75	76	75	75	76	72	71	73
Kaposi Sarcoma	52	48	75	69	60	80	40	40	40

\* Non-applicable gender.